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g gravitational force
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LB (Luria Bertani) Broth
LGIC ligand-gated ion channel
EPS lipopolysaccharide
mRNA messenger RNA
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PGR polymerase chain reaction
PFA paraformaldehyde
PEI polyethylenimine
pH -logio (hydrogen ion concentration)
pH, intracellular pH
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RT-PCR reverse-transcriptase polymerase chain reaction
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Summary
Recently it has been reported that some receptors normally found in the 
nervous system may also be present on immune cells, including T-cells and 
neutrophils (Bergeret etal., 1998; Wheeler etal., 2000; Froh et.al., 2002). 
This includes suggestions that these receptors may regulate immune cell 
activation. Functional data also exists to indicate that GABAa receptors 
may be present in mouse T-cells (Tian etal., 1999). The initial aim of the 
project was to determine if such receptors might play a similar role in human 
leukocytes. We used RT-PCR and real-time quantitative TaqMan RT-PCR 
to screen for receptor subunit mRNAs in human leukocytes. Many of these 
subunit mRNAs were detected in human PBMC and Jurkat cells, although 
quantitative studies showed these were expressed at low levels.
GABAa-R a l ,  a3, p2, 5 and e subunit mRNAs were detected in PBMC and 
Jurkat cells, while the GlyR p subunit mRNA detected in Jurkat cells only. 
Functional studies were carried out by studying the effects of GABA and 
glycine on the increase in intracellular [Ca^T in response to 1 nM fMLP or 1 
mg/ml LPS in rat and human PBMC and neutrophils. Based on the 
published rat data, GABA and glycine were expected to inhibit this release. 
However, application of neither GABA nor glycine led to a reduction in the 
response to either agonist. In rat and human PBMC, some reduction of 
intracellular [Ca^ "^ ] was detected upon application of 1 mM GABA. These 
results indicate that mammalian neutrophils do not express functional 
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The most exciting phrase to hear in science, the one that 
heralds new discoveries, is not Eureka! (I fou n d it!) but 
rather, that*s funny,..,  "
-  Isaac Asimov
Chapter 1
Introduction
1.1 -  Interdctions between the immune and nervous systems
Recent advances in the study of interactions between the immune and nervous 
systems has led to increasing experimental and clinical evidence indicating the 
occurrence of bidirectional communication between the two systems. A vast 
network of communication exists, as primary (bone marrow and thymus) and 
secondary (spleen and lymph nodes) lymphoid organs are supplied with an 
autonomic (mainly sympathetic) efferent innervation and with an afferent sensory 
innervation (Felten et a l, 1985; Cavagnaro, 1986; Fatani et al, 1986; Felten et a l, 
1988; Artico et a l, 2002).
The nervous and immune systems communicate in two different ways: 
neurohormones and neurotransmitters use anatomical and functional pathways 
related to the pituitary and autonomic systems, and the immune system is able to 
modulate some nervous functions via the action of a group of soluble proteins 
called cytokines (Bongioanni, 1993). Developments in immunohistochemistry 
have enabled assessment of a differential localisation of intramedullary nerve fibres 
in bone marrow. In the rat, noradrenergic fibres and spinal nerve branches supply 
the bone marrow (Felten et a l, 1985; Felten et a l, 1988; Tabarowski et a l, 1996). 
In mice, immunoreactivity for tyrosine hydroxylase (TH), a marker for sympathetic 
nerves, was found around large vessels, with occasional TH-positive fibres ending 
in the bone marrow (Tabarowski et a l, 1996). The intimate association between 
nerve fibres and haematopoietic and stromal cells is considered important for neural 
modulation of haematopoiesis, including maintenance of the blood-marrow 
interface, control of peripheral blood cell number and mobilisation of colony 
forming cells (Tabarowski et a l, 1996; Afan et a l, 1997).
A functional role for cholinergic innervation of the haematopoietic compartment 
was also recently proposed in view of the demonstration of choline 
acetyltransferase (ChAT)-immunoreactive nerve fibre-like structures in rat femur 
bone marrow around haematopoietic islets (Artico et a l, 2002). Also, accessory 
immune cells (e.g. monocytes and macrophages) and lymphocytes have been
shown to express specific membrane receptors for several neurotransmitters and 
neuropeptides, including adrenergic, dopamine and cholinergic receptors (Halper et 
al, 1984; Bering et a l, 1987; Maslinski et a l, 1992; Costa et a l, 1995; Ricci et a l, 
1995; Bondy et a l, 1996; Hiemke et a l, 1996; Bany et a l, 1999; Tayebati et al, 
2002; Wang et a l, 2002; Dantzer & Wollman, 2003; Mignini, 2003). These 
receptors have been shown to respond in vivo and in vitro to the neural substances 
and their manipulation can alter immune responses.
Neuromediators and neuropeptides can be found at sites of immune and 
inflammatory reactions (Nio et al, 1993; Tissot et al, 1988; Kawashima and Fujii,
2000) and modulate immune responses (Goetzl et al, 1990). Changes in immune 
function can also influence the distribution of nerves and the expression of neural 
receptors in lymphoid organs (Mignini et al 2003). Therefore, in the immune 
system, the same transmitter originating from neural and non-neural sources may be 
involved in the control of immune defences. In humans, acetylcholine and the 
synthesizing enzyme, choline acetyltransferase (ChAT), have been found in 
epithelial cells (airways, alimentary tract, urogenital tract, epidermis), mésothélial 
cells (pleura, pericardium), endothelial cells, muscle and immune cells 
(mononuclear cells, granulocytes, alveolar macrophages, mast cells). The 
widespread expression of non-neuronal acetylcholine is accompanied by the 
ubiquitous presence of cholinesterase and nicotinic and muscarinic receptors 
(Wessler et a l, 2001; Wessler et a l, 2003).
1.2 -  Leukocytes
Leukocytes or white blood cells, are responsible for both innate and adaptive 
immune responses. These cells respond to pathogens, cell injury and allergic 
reactions. In humans there are approximately 7x10^  leukocytes per ml in whole 
blood (Roitt et al, 1998). Cells of the immune system are present throughout the 
body. Some are resident within tissues, where they respond to local trauma and 
alert the defence system, while others circulate in body fluids, from where they are 
recruited to sites of infection. In defending the body against pathogens, white blood
cells cooperate with each other first to recognise the microorganism as an invader 
and then to destroy it. Three main types of leukocytes exist which are shown in 
Figure 1.
Leukocytes all originate in the bone marrow, from where they migrate to develop 
further and perform their functions. All blood cells are continuously regenerated by 
the process called hematopoiesis, which is believed to be the function of a single 
precursor cell called the pluripotent stem cell. These cells then undergo 
differentiation to give rise to the common myeloid and lymphoid progenitor cells. 
Lymphocytes are of lymphoid progenitor origin, while phagocytes and monocytes 
are of myeloid origin (Figure 2).
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Figure 2: Origin and differentiation of leukocytes (Adapted from Roitt et al., 
1998). The haemopoietic cells are derived from pluripotent stem cells. 
These cells divide and differentiate into the more specialised progenitor cells 
that give rise to the lymphoid lineage and the myeloid lineage. The common 
lymphoid progenitor differentiates into T cells, B cells and natural killer cells. 
The myeloid progenitor cell differentiates to produce the three types of 
granulocytes: the eosinophil, the neutrophil and the basophil. It also 
differentiates into the mast cell and the monocyte, which in turn gives rise to 
the macrophage.
1.2.1 -  Lymphocytes: types, structure and function
The lymphocytes make up 20 -  40% of total immune cell population in blood, and 
are 6 -  8 pm in diameter. These cells are divided into various classes with respect 
to their recognition molecules and the functions that they are programmed to 
perform. There are two main types of lymphocytes: the B cells and T cells (Figure 
3A). B cells have surface receptors which recognise specific antigens. Upon 
recognising its specific antigen, B cells multiply and differentiate into plasma cells, 
which then produce large amounts of antibody (Reth, 1995). On activation by 
infection, B cells divide and differentiate into plasma cells that make antibodies 
(Owens, 1988). T cells have more diverse functions, which they perform on 
interaction with other cells of the immune system and cells infected with 
intracellular pathogens such as viruses. When activated by infection, T cells 
differentiate into effector T cells with various functions. One group of T cells 
interacts with B cells and assists division, differentiation and antibody production, 
while another group interacts with mononuclear phagocytes (Owens, 1988; Owens, 
1991; Springer, 1994). These two groups of cells are the T-helper (Th) cells. A 
third group of cells are the T-cytotoxic (Tc) cells, which are responsible for the 
destruction of infected host cells (Roitt et al., 1998; Abbas et a l, 2000).
Both B and T cells originate from lymphoid precursors in the bone marrow, but 
whereas B cells complete their maturation in the bone marrow before entering the 
circulation, T cells leave at an immature stage and migrate in the blood in the 
thymus, where they complete their maturation (Germain et a l, 2002; Spits, 2002). 
T- and B cells also take up residence in lymph nodes, the spleen and other tissues 
where they encounter antigens, continue to divide by mitosis and mature into fully 
functional cells (Roitt et a l, 1998; Abbas et a l, 2000; Niiro & Clark, 2002).
In addition to small lymphocytes, the blood contains large granular lymphocytes, 
also known as natural killer cells (Figure 3C), which function in innate immunity 
and are important in the defence against viral infections (Lanier et al, 1996). These 
cells make up 1.5 -  2% of leukocytes and have a diameter of ~ 8 -  12 pm. Unlike
the T and B cells, natural killer cells do not express antigen receptors, although they 
do contain azurophilic granules (Roitt et a l, 1998).
1.2.2 -  Phagocytes: types, structure and function
Phagocytes mediate innate immune responses by phagocytosing microorganisms, 
and are the first line of defense against infection. Phagocytes can be divided into 
two main groups: the agranular phagocytes, which include monocytes and 
macrophages, and the granular phagocytes, which include neutrophils, eosinophils 
and basophils. The latter group are also collectively called granulocytes because 
of their prominent cytoplasmic granules, which contain reactive substances that kill 
microorganisms and enhance inflammation (Razin et a l, 1995).
The most abundant leukocytes are the neutrophils (60 -  70% of leukocytes), which 
are also the most prominent of phagocytes. These cells are 10 -  12 pm in diameter 
and possess a very characteristic nucleus, where it is divided into 2 - 8  lobes which 
are connected by thin strands of chromatin (Figure 3D). However, 1 -  2% of 
neutrophils have a horse-shoe shaped nucleus. In addition to the usual complement 
of organelles, they also contain two types of granules. Primary granules (or A 
granules) contain lysosomal enzymes and secondary granules (or B granules), 
which are the specific granules of the neutrophils, containing enzymes with strong 
bactericidal actions (Roitt et a l, 1998; Abbas et al, 2000).
Unlike most cells of the body which are associated with specific locations, 
neutrophils migrate from the blood stream to various parts of the body, including 
the kidneys, lung and gut (Morris et a l, 2001). These cells possess general 
pathogen-recognition mechanisms, and play a central role in inflammatory 
processes (Nussler et a l, 1999). Large numbers invade sites of infection and begin 
to phagocytose tissue debris and foreign bodies, e.g. bacteria. These are the first 
wave of cells invading sites of infection, and their phagocytotic activity is 
stimulated if invading microorganisms are "tagged" with antibodies.
Eosinophils make up 2 -  5% of leukocytes and are 12 -  15 pm in diameter. The 
nucleus usually has only two lobes and almost all of the cytoplasm is filled with the
specific granules (Figure 3F). Aside from the usual complement of organelles, 
eosinophils contain some large rounded vesicles (up to 1 pm) in their cytoplasm. 
These specific granules contain enzymes that are otherwise found in lysosomes. 
The granules contain the enzymes, histaminase and sulphatase, which break down 
histamine and leukotrienes, which may dampen the effects of their release by 
basophils or mast cells (Wardlaw et a l, 1995).
Basophils make up 0 .5 -1%  of leukocytes and have a diameter of ~ 14 pm. These 
cells have a 2 or 3 lobed nucleus. The lobes are usually not as well defined as in 
neutrophilic granulocytes and the nucleus may appear S-shaped (Figure 3E). The 
granules are not as numerous as those in eosinophils, and contain heparin, 
histamine, lysosomal enzymes and leukotrienes. Heparin and histamine are 
vasoactive substances and therefore facilitate the access of other lymphocytes and 
of plasma-bome substances of importance for the immune response (e.g. 
antibodies) to e.g. a site of infection. The release of the contents of the granules of 
basophils is receptor-mediated. Antibodies produced by plasma cells (activated B- 
lymphocytes) bind to Fc-receptors on the plasma membrane of basophils. If these 
antibodies come into contact with their antigens, they induce the release of the 
contents of the basophil granules (Razin et a l, 1995). Mast cells are bone marrow 
derived cells found in connective tissues. They contain granules containing 
substances (e.g. histamine) that contribute to inflammation.
The non granular monocytes are larger than granulocytes, make up 3 -  8% of 
leukocytes and are ~ 12 -  18 pm in diameter. The monocyte has a C-shaped 
nucleus (Figure 3B) and contains granules which in appearance and content 
correspond to the primary lysosome granules of neutrophils. Once monocytes enter 
the connective tissue they differentiate into macrophages. At sites of infection 
macrophages are the dominant cell type after the death of the invading neutrophils. 
Tissue macrophages are large cells characterised by an extensive cytoplasm with 
numerous vacuoles, often containing engulfed materials. They are the general 
scavenger cells of the body, phagocytosing and disposing of dead cells and cell 
debris. In both innate and adaptive immune responses, one of their roles is to 
engulf, kill, and break down microorganisms. Macrophages have mechanisms for 
recognising and reacting to pathogens, which make them important cells of innate






Figure 3: Micrographs of Leishman’s stained immune cells. (A) Lymphocyte 
(T- and B-cells); (B) Monocyte; (C) Natural killer cell; (D) Neutrophil; (E) 
Basophil and (F) Eosinophil. Adapted from Abbas etal. (2000).
Lymphocytes and monocytes are also collectively called agranulocytes or 
mononuclear cells due to their appearance. These cells can be isolated from other 
immune cells as a crude preparation called peripheral blood mononuclear cell 
(PBMC) fraction. This preparation comprises mainly of T and B cells (~ 90%) and 
is commonly used in studies where lymphocytes in general are of interest.
1.3 -  Presence of neurotransmitters in immune cells
Neurotransmitters such as acetylcholine, serotonin and dopamine have all been 
reported to be present in the blood of several mammals, including humans (Fujii, et 
al, 1997; Yamada, et al, 1997; Kawashima et al, 1998; Kawashima et a l, 2000; 
McKenna et a l, 2002; Wang et a l, 2002; Ghosh et a l, 2003; Fajardo et a l, 2003; 
Gordon et a l, 2003). Acetylcholine, in particular has been detected in the blood 
and plasma of various mammals and has been suggested to have a role in immune 
modulation. (Maslinkski, 1989; Rinner and Schauenstein, 1991; Kawashima and 
Fuji, 2000). Acetylcholine is a main peripheral, autonomic and brain excitatory 
neurotransmitter, and increasing evidence indicates that mammalian peripheral 
blood lymphocytes possess a cholinergic system and that ACh acting as an 
autocrine or paracrine factor may regulate immune cell fimction (Bany et a l, 1999; 
Fujii and Kawashima, 2001; Wang et a l, 2002). Also, ACh and various muscarinic 
and nicotinic ACh receptor agonists have been shown to modulate lymphocyte 
function and metabolism (Kawashima & Fujii, 2000). In particular, Fujii and 
Kawashima (2000), while examining the effects of ACh and muscarinic agonists on 
the intracellular free Ca^  ^concentration ([Ca^^J in human T-cell (CEM) and B-cell 
(Daudi) lines, provided the first evidence that ACh released from T-lymphocytes 
triggers nuclear signalling and upregulation of gene expression in T- and B- 
lymphocytes via muscarinic receptors. Functional and molecular studies have also 
established the presence of both the ionotropic nicotinic acetylcholine (nACh) and 
the metabotropic muscarinic (mACh) receptors in several human immune cell 
types, particularly in T and B cells (Link et a l, 1992; Fujii et a l, 1999; Kawashima 
et a l, 1998; Tayebati, et al 2002). The presence of nicotinic ACh receptors on 
lymphocytes has been demonstrated by radiolabeling, fluorescent labelling and 
immunocytochemistry (Kawashima & Fujii, 2000). Recent molecular biological
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studies revealed the expression of nicotinic receptor a3, a5 and p4 subunits in 
human thymocytes (Mihovilovic & Roses, 1991; Mihovilovic & Roses, 1993) and 
the a3 and a4 subunits in human circulating lymphocytes (Hiemke et a l, 1996). 
Also, Skok et.al (2003) showed that functional nicotinic ACh receptors are 
expressed on B-cell lines.
Enhanced cholinergic stimulation is a well-known phenomenon in patients with 
bronchial asthma, and acetylcholine might stimulate alveolar macrophages to 
release neutrophil, monocytes and eosinophil chemotactic factors (Sato et a l, 
1998). To date, the presence of ACh in human blood and ACh synthesis by choline 
acetyltransferase (ChAT) has been reported in T and B-cells, granulocytes, 
macrophages and mast cells (Kawashima and Fujii, 2000; Wessler et al, 2001; 
Tayebati et a l, 2002). The gene encoding ChAT is also expressed in human 
leukemic T cell lines. This is supported by findings that human T cell lines, but not 
B cell lines, possess high ChAT activity and high intracellular ACh content (Fujii et 
al, 1999). Also, the majority of acetylcholinesterase (AChE) activity appears to 
reside in T cells (Topilko & Caillou, 1985; Szelenyi et a l, 1987; Paldi-Harris et a l, 
1990). Ando et al (1999) detected the expression of mRNAs encoding three 
different AChE isoforms in human mononuclear lymphocytes (mainly T cells) and 
leukemic T cell (CEM) and B cell (Daudi) lines using RT-PCR. It has therefore 
been hypothesised that blood ACh may originate primarily from T cells and interact 
with ACh receptors on themselves and other blood cells, serving as an 
immunomodulator (Fujii and Kawashima, 2001). Recent studies on human 
macrophages by Wang et al (2002) have shown that the nicotinic acetylcholine 
receptor a?  subunit is necessary for cholinergic inhibition of TNF release, making 
it an essential regulator of inflammation.
Dopamine, a catecholamine neurotransmitter, has been reported to influence the 
growth and proliferation of lymphocytes, and pharmacologically relevant doses of 
dopamine have been shown to modulate T cell functions significantly (Saha et a l,
2001). This information correlates with findings that significantly elevated plasma 
dopamine levels are observed in humans during stress, and suppression of T cell 
functions during stress is a well-known phenomenon. Saha et al (2001) evaluated
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the effect of the dopamine level attained in the plasma of individuals with stress on 
the proliferation and cytotoxicity of CD4+ and CD8+ T cells in vitro. At elevated 
physiological concentrations, dopamine was found to significantly inhibit the 
proliferation and cytotoxicity of CD4+ and CD8+ T cells in vitro. This dopamine- 
mediated inhibition of proliferation was more marked on CD8+ T cells than on 
CD4+ T cells. The underlying mechanism was found to be a D1 class of dopamine- 
receptor-mediated stimulation of intracellular cAMP. In a similar experiment, 
Ghosh et al (2003) studied the effects of dopamine on the release of cytokines fi*om 
activated human T cells. They observed that dopamine inhibited anti-CD3 mAb- 
induced release of both Thl and Th2 cytokines, IL2, IFN-gamma and IL4 fi-om T 
cells. Dopamine was found to suppress non-receptor tyrosine kinases, Lck and Fyn 
expression. These are the initial and pivotal signalling steps in T cell receptor 
(TCR) mediated different down stream signalling cascades, leading to cytokine 
release and subsequent clonal expansion of these immune effector cells. Dopamine 
D2, D3, D4 and D5 receptor expression on human leukocytes has been identified by 
flow cytometric techniques (McKenna et a l, 2002), radioligand binding assays and 
immunocytochemistry (Amenta et a l, 2002). The studies demonstrated that while 
B cells and NK cells showed consistently high expression, T cells and monocytes 
showed low expression of dopamine receptors, whereas neutrophils and eosinophils 
showed moderate expression.
The monoamine transmitter serotonin (5-hydroxytryptamine, 5-HT) also plays 
several roles in the immune system and the expression of a number of its receptor 
subtypes in the immune cells has also been reported (Lima & Urbina, 2002; Fajardo 
et a l, 2003; Gordon et a l, 2003). Stefulj et al (2000) used RT-PCR methods to 
examine the mRNA expression of 5-HT receptors in the cells of lymphoid tissues of 
the rat. 13 rat 5-HT receptor genes were cloned and examined in isolated spleen, 
thymus, and peripheral blood lymphocytes, as well as in mitogen-stimulated spleen 
cells. Positive signals were obtained for a number of 5-HT receptor mRNAs in all 
three compartments. Mitogen (ConA and PWM) stimulated cells additionally 
expressed mRNA corresponding to the 5HT-3 receptor. Also, lymphocytes have 
been reported to carry active transport systems for serotonin. Faraj et al (1994) 
showed that lymphocytes isolated fi'om the blood of normal human subjects 
contained a high-affinity uptake system for [^H]5-HT. The uptake of [^H]5-HT was
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potently inhibited by the antidepressants elomipramine, imipramine, fluoxetine and 
fluvoxamine, whieh are specific for the 5-HT transporter.
1.4 -  Ligand-gated ion channels
Ligand-gated ion channels (LGIC), or ionotropic receptors, are receptor proteins 
that are also ion channels (or are directly linked to an ion channel). Binding of the 
transmitter to the receptor changes the channel associated with it from the open 
(conducting) to the closed (non-conducting) conformation. Vertebrate LGICs 
include y-ammobutyric acid type A (GABAa) and type C (GABAc), glycine, 
nicotinic acetylcholine (nACh), serotonin type 3 (5 -HT3), some invertebrate 
anionic glutamate receptors and P2X receptors.
1.4.1 -  Structure of ligand-gated ion channels
Ligand-gated ion channel receptors are members of a superfamily of hetero 
pentamerie glycoprotein receptors that span the membrane to form an ion channel 
(Macdonald & Twyman, 1991; Vemallis et a l, 1993). The five subunits can be 
homomeric or heteromerie. The receptors consist of a large extracellular N- 
terminus (containing a signal peptide, a cysteine bridge and glycosylation sites) and 
a short C-terminus (Figure 4A). There are also 4 hydrophobic transmembrane 
domains, M1-M4, where the polypeptides coil into alpha helices and span the 
membrane (Figure 4B), although there have been some reports to suggest that the 
polypeptides form a p-sheet in the M2 region. Between M3 and M4 is a large 
intracellular loop, which is the most variable region between subunits (Moss and 
Smart, 2001). This region may contain protein kinase A (PKA), protein kinase C 
(PKC), and tyrosine kinase phosphorylation sites. M2 is crucial for receptor gating 
and selectivity, as this region lines the channel pore and constitutes the most 
conserved part of the receptor. Binding of one or more molecules of the transmitter 
to the receptor protein induces it to shift its 3D shape (or conformation) slightly, 
altering the structure of the ion channel in a way that opens it. Once the transmitter 
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Fig 4: (A) Model of the structure of a ligand gated ion channel. This is a pentamerie structure, 
composed of 5 subunits. Each subunit has 4 transmembrane domains named M1-M4 which is 
also depicted in (B) (Adapted from Bear et al, 1996). M2 lines the channel pore and is thought 
to be ion selective and a large intracellular loop is present between M3 and M4. Figures (A) and
(B) also show each subunit contains a large extracellular N-terminus and a short C-terminus. 
Figure (C) shows a cross-section of the five assembled subunits of a ligand gated ion channel. 
When the transmitter binds to its receptor, the channel pore opens allowing ions to flow 
through into the cytoplasm of the cell. (Adapted from Bate etal., 1996)
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Synaptic targeting and clustering of ligand gated ion channel receptors are mediated 
by the interaction of the intracellular domains of these receptor subunits with the 
cytoskeleton (Moss and Smart, 2001). The intracellular domains of individual 
receptor subunits can interact with a range of diverse proteins including cytoskeletal 
elements, microtubule-binding proteins, neurotransmitter transporters, protein 
kinases and other signalling molecules.
1.4.2 -  GABAa Receptors
In the central nervous system G ABA is a major inhibitory transmitter. G ABA is 
synthesised from glutamic acid, the major excitatory neurotransmitter, by one of 
two forms of glutamic acid decarboxylase (GAD) (Erlander and Tobin 1991). It is 
released from GABAergic neurons and binds to its three receptors: the ligand gated 
GABAa and GAB Ac receptors and the G -  protein coupled GAB A s receptor 
(Olsen and Tobin, 1990; Macdonald and Olsen, 1994; Chebib and Johnston, 1999).
Functional GABAa receptors are a complex of five subunits that form an intrinsic 
chloride ion selective channel. GAB A binds to GABAa receptors allowing a 
passive flow of negatively charged chloride ions through the ion channel pore (as 
shown in Figure 4C), which usually results in hyperpolarisation of the cell 
membrane. However, in some neurons the activation of GABAa receptors has been 
shown to lead to an efflux of chloride ions and a depolarisation of the cell 
membrane due to higher [CFjmt than [CFJext (Bormann, 1988; Macdonald and 
Olsen, 1994; Sieghart, 1995; Wagner gf a/., 1997).
In mammals, GABAa receptor subunits are highly heterogenous. Nineteen 
subunits encoded by different genes have been cloned to date and form seven
families, many with multiple isoforms: a  (6 isoforms), P (3 isoforms), y (3
isoforms), p (3 isoforms) and one each of 6, 8, 7C and 0 (Davies et al, 1997; 
Hedblom et .al, 1997; Bonnert et al, 1999; Cherubini & Conti, 2001). The p 
subunits, identified in the retina and also present in other brain structures, are 
thought to co-assemble into homomeric channels that are highly sensitive to G ABA
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and insensitive to the GABAa receptor antagonist bicuculline, forming a distinct 
receptor class, called GAB Ac receptors (Bormann et al, 1995; Bormann et ai, 
2000). However, p subunits can co-assemble with other subunits to form 
heteromerie GABAa receptors (Qian & Ripps, 1999). The isoforms of each subunit 
(e.g. a l -  a6) typically exhibit amino acid sequence identities of 70 -  80%, 
whereas 30 -  40 % identities are found between different subunits of GABAa 
receptors (Liiscber, 2002). The relationship between the amino acid sequences of 
rat GABAa receptor subunits are depicted by the phylogenetic tree in Figure 5. 




















Figure 5: Phylogenetic tree  of the  d ed u ced  am ino acid se q u e n c e s  of ra t GABAa 
recep to r su b u n its  (A dapted from Cherubini & Conti, 2001). The length of each  
branch of the  tree  co rre la tes  with evolutionary  d is tan ce  betw een the  different 
po lypeptides.
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The molecular masses of the subunits vary between 48,000 kDa (y2) and 64,000 
kDa (a4), and the most common native receptor stoichiometry is 2a, 2P and ly/0/8 
subunits (Farrar et al 1999). The recently identified subunit 0, cloned from rat 
striatum, can also coassemble with a2, Pl, yl (Whiting, 1999). Also, alternative 
splicing generates further increases in diversity. For example, the y2 subunit gene 
generates two splice variants, y2L and y2S, that exert different functions (Cherubini 
& Conti, 2001).
The proximity of GABAa receptor genes on individual chromosomes may be 
related to their coordinate temporal and spatial regulation (Tyndale et a l, 1995). 
The chromosomal locations may therefore provide insight into the regulation of the 
genes, and possibly provide assistance in understanding which receptor subunits 
combine together in vivo to form functional channels. For example, the major
isoform of the GABAa receptor in the brain consists of a l ,  P2, and y2 subunits 
(Laurie et al, 1992; Benke et a l, 1994; Macdonald & Olsen, 1994; Rabow et al, 
1995; McKeman & Whiting, 1996) and they have been found to colocalise in 
specific brain regions (Persohn et a l, 1992; Wisden et a l, 1992). Most of the 
subunit genes are clustered on different chromosomes, indicating gene duplication
as well as cluster duplication. The al/p2/y2/a6 cluster is located on human
chromosome 5, a5/p3/y3 on chromosome 15, a2/p i/y l/a4  on chromosome 4,
a3/s/0 on chromosome X, and pi and p2 on chromosome 6. The 71 subunit gene
is on chromosome 5 but is not clustered with the other four, and the Ô subunit is 
alone on chromosome 1 (Tyndale e ta l, 1995).
1.4.3 -  Glycine Receptors
Glycine was first identified as an inhibitory neurotransmitter by Aprison and 
Werman (1965), and Davidoff et al (1967), who described in detail the distribution 
of glycine throughout the central nervous system. Glycine has been found to be the 
main inhibitory transmitter in hindbrain areas (Aprison et al, 1978), and its effect is
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mediated through the activation of high affinity receptors localized on neurones of 
the spinal cord, medulla and pons (Young et a l, 1973). Functional studies have 
shown that glycine hyperpolarises postsynaptic motor neurons by increasing 
chloride conductance (Werman et a l, 1967; Curtis et a l, 1968a; Curtis et a l, 
1968b).
The glycine receptor molecule was first purified as strychnine binding sites in 
synaptic membrane fractions of adult rat spinal cord (Pfeiffer & Betz, 1981; Pfeiffer 
et a l, 1982). It was found to compose of three distinct polypeptides: two
glycoproteins of 48 kDa and 58 kDa, termed the a  and p subunits respectively, 
and a 93 kDa cytoplasmic protein termed gephyrin (Pfeiffer & Betz, 1981; Pfeiffer 
et al, 1982). Three different a  subunit isoforms have been identified in the rat: the 
originally purified 48 kDa a l  subunit, a 49 kDa a2 subunit (Becker et a l, 1988; 
Kuhse et a l, 1990a; Akagi et a l, 1991) and a 50 kDa a3 subunit (Kuhse et a l, 
1990b). Most glycine receptors in the CNS are probably composed of a  and p 
subunits with an invariant subunit ratio of 3a:2P (Betz et al, 1999; Langosch et
al, 1988). However, in vitro, homomeric a  subunits can also produce functional 
ion channels (Grenningloh et al, 1987; Betz et al, 1999). Whilst homomeric 
glycine receptors can assemble from a-subunits, either in early development in vivo 
or from recombinant techniques to form glycine receptors with a similar 
pharmacology to adult spinal cord a/p  heteromerie glycine receptors, they do so 
with low efficiency. Co-expression of recombinant a and P subunits substantially 
increases the efficiency of expression (Grenningloh et a l, 1990a; Handford et a l, 
1996) and produces glycine receptors with an invariant stoichiometry, like that of 
adult spinal cord glycine receptors (Langosch et a l, 1988; Kuhse et a l, 1993). 
However, p subunits alone do not readily form glycine receptors, indicating that 
their ability to promote receptor expression and govern subunit stoichiometry arises 
through interactions with a subunits (Rajendra et a l, 1997).
A high degree of homology exists between the deduced amino acid sequences of a  
subunits (82 %), whereas the identity between the a l  and P subunits is 47 %
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(Grenningloh, 1990b, Becker, 1992). The evolutionary distances between the 




Figure 6: Phylogenetic tree of the deduced amino acid sequences of rat glycine receptor 
subunits (Feng & DooLittle, 1990). The length of each branch of the tree correlates with the 
evolutionary distance between the different polypeptides.
1.4.4 -  GABAa and glycine receptor pharmacology
GABAa receptors are the sites of action of a large number of clinically usefiil 
neuroactive drugs (Olsen et a l, 1991a; Ticku, 1991; Sieghart, 2000). By definiton, 
GABAa receptors are linked to chloride channels, and are activated by isoguvacine, 
allosterically modulated by barbiturates and benzodiazepines, and antagonised by 
bicuculline (Burt & Kamatchi, 1991; Macdonald & Twyman, 1991; Olsen et a l, 
1991b; DeLorey & Olsen, 1992). Benzodiazepines (e.g. valium and librium) 
modulate the actions of G ABA, acting at a site different from the agonist 
recognition site or the barbiturate site. Functionally they enhance GABAa- 
receptor-mediated inhibition by altering the rate of chloride channel opening that 
follows activation of the receptor. The benzodiazepine mode of action permitted 
the purification of the GABAa receptors by benzodiazepine affinity 
chromatography, and it has also been shown that both the affinity and efficacy of 
benzodiazepines is determined by the a  and p subunit present in the receptor 
(Hadingham et a l, 1993; Sieghart. 1995; Hadingham et a l, 1996; Whiting, 1999).
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Confirmatory evidence for a specific benzodiazepine site comes from molecular 
biology, where the a , p, and y subunits of the receptor have been assembled in 
various cell lines (Olsen & Tobin, 1990). Studies have shown that benzodiazepines 
bind with high affinity to the GABAa receptor at an allosteric modulatory site
situated on the a  and y subunit interface (Stephenson, 1995; Barnard et a l, 1998; 
Moss and Smart, 2001).
Many pharmacological agents act on the GABAa receptor including, general 
anesthetics and convulsants such as bicuculline, penicillin G, and p-carbolines, and 
GAB A analogues such as muscimol (Barnard et a l, 1987; Burt and Kamatchi, 
1991; Ticku, 1991). Other allosteric modulators of GABAa receptors include the 
barbiturate drugs, non-competitive chloride channel blocking agents (including 
picrotoxin, t-butylbicyclophosphorothionate (TBPS), certain neurosteroids, the 
avermectin anthelminthic agents Zrf^, ethanol and the anti-convulsant drug, 
loreclezole (Cherubini et a l, 1991; Macdonald & Twyman, 1991; Smart et a l, 
1991; Whiting et a l, 1997; Schmid et a l, 1999, Hosie et a l, 2003). The different 
GABAa receptor subunits have different sensitivities to G ABA and to modulatory 
drugs, which bind to distinct sites within the receptor complex (Stephenson, 1995, 
Whiting et a l, 1999), which has allowed dissection by site-directed mutagenesis, 
leading to identification of amino acid residues involved in channel formation, 
subunit interactions, phosphorylation susbstrates, and ligand-binding site domains.
Unlike the GABAa receptor, the known agonist profile of the glycine receptor is 
limited to only a few ligands. At least two separate regions in the N-terminal 
extracellular domain contribute to the binding site for glycinergic agonists and 
strychnine (Rajendra et a l, 1997). A number of amino acids have been shown to 
mimic the action of glycine in depressing spinal cord neuron firing rates including 
beta-alanine, taurine, L- and D-alpha-alanine, L-serine and D-serine (Curtis and 
Watkins, 1960; Werman et a l, 1968). Also, these inhibitory efficacies parallel the 
ability of these amino acids to displace the high-affinity antagonist [^H] strychnine 
from the receptor, indicating a largely competitive interaction between glycinergic 
agonists and strychnine (Young and Snyder, 1973).
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Channel activation by glycine is competitively antagonised by strychnine albeit in a 
noncooperative way (Schmieden et a l, 1989; Sontheimer et a l, 1989; Aprison, 
1990). Besides strychnine and its derivatives, there are only a few ligands binding 
to the glycine receptor with affinities in the low nanomolar range; these include the 
steroid RU 5135 (3a-hydroxy-16-imino-5p-17-aza-androstan-11 -one) and 1,5- 
diphenyl-3,7-diazaadamantan-9-ol. Picrotoxin and picrotoxinin are noncompetitive 
inhibitors and therefore thought to interact with the anion pore of the glycine 
receptor. Different affinities for this alkaloid (in the micromolar range) have been 
reported for glycine responses recorded from a variety of CNS regions at different 
developmental stages (Davidoff and Aprison, 1969; Evans, 1978; Barker et a l, 
1983) pointing to the heterogeneity of the respective glycine receptors.
1 .5 - Extraneuronal functions of GABA and glycine
GABAa mediated responses are not found exclusively in the central nervous 
system, and several reviews have focussed on the possible role of GABA outside 
the mammalian nervous system (Tanaka, 1985; Erdo and Wolff, 1990; Erdo and 
Wekerle, 1990). GABA and its synthesising enzyme GAD, have been detected in 
well-defined structures of the gastrointestinal system (Hills et al, 1987, Hills et a l, 
1988), and autoradiographic studies have shown GABA-accumulating cells to be 
present in the duodenum (Gilon et a l, 1987). GABAa receptors serve to reduce 
hormone secretion in components of the endocrine system, including glucagon- and 
somatostatin-secreting cells of pancreatic islets (Michalik and Erecinska, 1992), 
catecholamine-secreting chromaffin cells of the adrenal medulla (Bormann & 
Clapham, 1985) and in several types of anterior pituitary cells (Valerio et a l, 1992).
Biochemical and autoradiographic studies carried out by Erdo et al (1989) revealed 
the presence of binding sites specific for GABA and muscimol in the rat stomach. 
Specific binding sites for [^H]GABA and [^HJmuscimol showing the characteristics 
of GABAa receptors, were demonstrated on gastric membranes. Specific muscimol 
binding sites were found in all regions of the stomach and were present in both the
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mucosal layer and the remaining tissue of the stomach. Oral pretreatment of the rats 
with GABA, selective GABAa receptor agonists, or inhibitors of GABA 
degradation protected the gastric mucosa against the ulcers induced by acidified 
ethanol, in both intact and vagotomized rats. These findings suggested GABAa 
receptors in the rat stomach may mediate mucoprotective effects. GABAa 
receptors have also been described in rat and rabbit uterus (Erdo, 1984) and in the 
guinea pig ileum (Ong & Kerr, 1982; Ong and Kerr, 1984). Also light and electron 
microscopy studies have revealed GABA immunoreactivity in the rat kidney 
(Parducz et a l, 1992). Another site for GABA and GABAa receptors is in the 
reproductive system, particularly in the ovary, fallopian tube and uterus (Laszlo et 
a l, 1989; Erdo et al, 1990; Majewska and Vaupel, 1991). In female reproductive 
organs GABAa receptors have been found to include a benzodiazepine-barbiturate- 
chloride-ionophore complex, similar to that of GABAa receptors in the central 
nervous system (Erdo and Maksay, 1988; Erdo and Wolff, 1990). Benzodiazepines 
acting at this receptor complex were shown to interfere with ciliogenesis in the 
oviduct. Also, Erdo and Wekerle (1990) studied the specific binding of [^H]GABA 
to seminal membranes of swines and rams, which showed pharmacological 
characteristics corresponding to GABAa type receptors, suggesting that GABA 
may have a direct effect on spermatozoa. Hu et al (2002) found that GABA can 
trigger mammalian sperm acrosome reaction and they presented evidence to show 
that rat spermatozoa contain GABAa receptors, composed of a5, p i and p3 
subunits. GABA and GAD have been shown to be present in rodent thymus gland 
(Cavallotti et a l, 1999), and the levels of GABA have been shown to increase 
following an immune response (Hall et a l, 1985) indicating that GABA may play a 
role in modulation of immune responses.
Outside the nervous system glycine receptors have been reported to be present in 
the liver (Kupffer cells) (Ikejima et al, 1997; Wheeler, 1999a; Froh et a l, 2002) 
and in neutrophils (Wheeler et al, 2000) and macrophages (Wheeler and Thurman, 
1999; Froh et a l, 2002). All these studies suggested that glycine serves to inhibit 
cell responses to inflammation. Studies conducted by Yamashina et al (2001) 
demonstrated the presence of glycine-gated chloride channels in bovine endothelial 
cells. Glycine was shown to inhibit endothelial cell proliferation in a dose- 
dependent manner, and growth factor-induced migration was also significantly
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blunted. Also, as glycine was shown to inhibit agonist (vascular endothelial growth 
factor) induced increases in [Ca^^i in endothelial cells, it was suggested that 
glycine may inhibit endothelial cell proliferation via inhibition of Ca^  ^ signalling. 
Other studies have shown that liver, lung and kidney cells exposed to endotoxin 
shock have increased survival rates upon application of glycine (Miller et a l, 1994; 
Ikejima et a l, 1996; Zhong et a l, 1999; Wheeler et a l, 2000)
1.6 -  Presence of GABA and glycine receptors on 
mammalian immune cells
A few studies have indicated that GABA and also glycine may play a role in 
immunomodulation. The possible role that glycine receptors may play in rat 
neutrophils was demonstrated by Wheeler et al (2000), where glycine was shown 
to inhibit agonist-induced increases in intracellular free calcium. Wheeler et a l, 
(2000) have shown some evidence that rat neutrophils may contain functional 
glycine-gated chloride ion channels. It was hypothesized that when glycine enters 
the cell, membrane hyperpolarisation occurs leading to an inactivation of voltage- 
gated calcium channels, and inhibits [Ca^^i release from intracellular stores. They 
demonstrated this by showing that upon administration of glycine to rat neutrophils, 
fMLP and LPS induced Ca^  ^ release was inhibited. Also, these responses were 
inhibited upon the application of strychnine, the competitive glycine receptor 
antagonist.
Bergeret et al (1998) and Froh et al (2002), have shown molecular evidence for 
the presence of a number of GABAa and glycine receptor subunits respectively. 
RNase protection assays, RT-PCR and western blotting experiments conducted by 
Froh et al (2002) provided evidence for the presence of glycine receptor a l ,  a2 
and P subunits in rat splenic and alveolar macrophages and neutrophils. Other 
studies have shown that application of glycine to rat alveolar macrophages and 
lipopolysaccharide (LPS) treated monocytes leads to decreased levels of superoxide 
and TNF-a production and increased levels of IL-10 expression (Wheeler and
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Thurman, 1999; Spittler et al 1999). The presence of GABAa receptors on immune 
cells was determined by Bergeret et al (1998) on PS 15 (mouse mastocytoma mast 
cell line) and H9 cells (human T cell line), where the GABAa a l ,  a2, a4 and pi 
subunits were detected in RT-PCR and immunoblotting studies. Bergeret et al 
(1998) investigated a possible contribution of GABA to the physiology of immune 
competent cells, and reported that GABA modulates T cell-mediated cytotoxicity, 
probably through GABAa receptors. Also the results showed a decreased 
cytotoxicity of T cells when added to GABA-treated targets indicating that GABA 
may also protect GABA responsive cells. Also, Tian et al (1999) described the 
possible presence of functional GABAa receptors on mouse T cells, where the 
application of GABA led to inhibition of anti-CD3 and antigen-specific T cell 
proliferation in a dose dependent manner. These responses were also obtained upon 
application of the GABAa receptor agonist, muscimol, were enhanced by 
pentobarbital and were blocked by picrotoxin and bicuculline. These studies 
suggest that both GABAa and glycine receptors could be present on immune cells, 
where they can mediate inhibition of immune responses, and that these receptors 
can be modulated in a similar way to their neuronal counterparts.
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AIM
There are recent reports providing pharmacological evidence for the presence of 
inhibitory receptors related to the GABAa and glycine ligand gated ion channel 
receptor families, on several different immune cell types, including T cells and 
neutrophils (Bergeret et al, 1998; Tian et al, 1999; Wheeler et a l, 2000). These 
reports included data suggesting a potential role for these receptor types in the 
downregulation of immune cell activation, leading to the inhibition of inflammatory 
immune responses. Such receptors may therefore be important targets for the 
development of drugs for the treatment of respiratory and inflammatory disorders. 
To date, however, there are no reports of the molecular isolation of functional 
LGICs from immune cells. The aim of my project therefore was to screen for the 
presence of inhibitory LGICs, in particular GABAa and glycine receptors, on 
human leukocytes.
RT-PCR and real-time quantitative TaqMan RT-PCR were used to screen for 
GABAa and glycine receptor subunit mRNAs in human leukocytes. 
Immunoblotting and immunofluorescence experiments were carried out to confirm 
the presence of GABAa a l  receptor subunit protein in human PBMCs and 
neutrophils as well as in the human T cell leukaemia cell line Jurkat J6 and in HL- 
60 cells, a human promyelocytic cell line. Finally, the effects of GABA and 
glycine on the increase in intracellular [Ca^ ]^ in response to InM fMLP or 1 mg/ml 
LPS was studied in rat and human PBMC and neutrophils, as an attempt to 





2.1 -  Jurkat J6 and HL-60 cells
Jurkat J6 cells were kindly provided by Dr Stephen Ward, Department of Pharmacy 
and Pharmacology, University of Bath.
HL-60 cells were obtained from the European Collection of Cell Cultures (ECACC 
number 98070106, deposited by Dr. Chris Bunce, Dept, of Medicine, University of 
Birmingham, UK).
2.2 -  Culture media and conditions
1 X RPMI 1640 medium (with L-glutamine and 25 mM HEPES) was purchased 
from GIBCOBRL. The medium was supplemented with 10% (v/v) fetal bovine 
serum (SIGMA) and 10,000 units/ml penicillin / lOmg/ml streptomycin (SIGMA).
2.3 -  Freezing media
The medium used to freeze Jurkat J-6 cells consisted of 50% (v/v) FBS, 20% (v/v) 
DMSO, 30% (v/v) 1 X RPMI 1640 medium (with L-glutamine and 25 mM 
HEPES).
The medium used to freeze HL-60 cells consisted of 90% (v/v) FBS, 10 % (v/v) 
glycerol.
27
2 .4 - Buffers
Table 1: Recipes for common buffers
Buffer Composition
10 X TEE 0.89 M Tris-HCl; 0.89 M boric acid; 20 mM EDTA, pH 8.0
TE 10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA
PBS 137 mM NaCl; 2.7 mM KCl; 10 mM Na2HP04; 2 mM 
KH2PO4, pH 7.4
LB 10 g tryptone; 5 g yeast extract; 10 g NaCl in 1L dd H2O




2.5 -  Isolation of human PBMC
Whole blood was collected into vacutainer bottles eontaining 15% (w/v) EDTA 
(Beckton Dickenson). To ensure maximum viability, cells were processed 
immediately. If storage was required the tubes were kept at 4° C for less than 12 
hours.
To isolate peripheral blood mononuclear cells, HISTOPAQUE® 1077 (SIGMA) 
was used as the density gradient (polysucrose, 57 g/L, sodium diatrizoate, 90 g/L). 
15 ml of HISTOPAQUE® 1077 was warmed to room temperature and added to a 50 
ml LeucoSep® tube (Greiner) containing a porous filter disc. This was centrifuged 
at 200 X g for 5 min to spin the HISTOPAQUE® 1077 to the bottom. 25 -  30 ml of 
freshly anticoagulated blood was then poured into the tube and centrifuged at 800 x 
g for 15 min at room temperature. Once centrifuged the sequence of tube contents 
from top to bottom was as shown in Figure 7.
Plasma





Figure 7: Sequence of tube contents in PBMC cell isolation fraction
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The plasma layer was aspirated off and PBMCs were harvested and washed 3 times 
in 10 ml ice eold PBS/1 mM EDTA and centrifuged at 300 x g for 10 min at 4° C. 
The purified PBMCs were then resuspended in 5 ml 1 x PBS.
2.6 -  Isolation of human neutrophils
Whole blood was collected into tubes eontaining 15% (w/v) EDTA (Beckton 
Dickenson). To isolate neutrophils 17 ml o f Polymorphprep (Invitrogen) at 20 °C 
was placed into 50 ml tubes. 25 ml of whole blood was carefully layered on to this 
and spun for 30 min at 500 x g. The sequence o f tube contents was as shown in 
Figure 8. Plasma and lymphocyte layers were aspirated off and the granulocyte 
layer was then transferred to a fresh 50 ml tube. PBS containing 0.2% (w/v) 
glucose was then added to 50 ml, and the cells spun at 300 x g for 10 min. The 
supernatant was poured off and the cell pellet resuspended in 7.5 ml ice-cold 0.2% 
(w/v) NaCl. Cells were mixed for 1 min and then 7.5 ml ice-cold 1.6% (w/v) NaCl 
was added. PBS (with 0.2% (w/v) glucose) was added to 50 ml and cells spun at 
200 X g for 10 min. This was repeated twice, and the cell pellet resuspended in 1 X 
PBS or the required assay buffer (see Table 10).
Plasma
 <---------------  Lymphocytes
 <---------------  Polymorphprep
Granulocytes (mainly neutrophils)
Red blood cells
Figure 8: Sequence of tube contents during isolation of human neutrophils
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2.7 -  Isolation of rat neutrophils
Whole blood was collected into tubes containing 15 % EDTA (Beckton 
Dickenson). To isolate rat neutrophils, HISTOPAQUE® 1077 (SIGMA) 
(polysucrose, 57 g/L, sodium diatrizoate, 90 g/L), and HISTOPAQUE® 1119 
(polysucrose, 60 g/L, sodium diatrizoate, 167 g/'L) were used as the density 
gradients. Both were warmed to room temperature prior to use.
12ml of HISTOPAQUE® 1119 was added to a 50 ml centrifuge tube, and 12 ml o f 
HISTOPAQUE® 1077 was gently layered onto this. 24 ml o f freshly 
anticoagulated whole blood was then carefully layered onto the upper gradient, and 
the tubes were centrifuged at 700 x g for 30 min at room temperature. Once 
centrifuged, two distinct opaque layers could be observed. The sequence o f tube 




^ Granulocytes (mainly neutrophils)
HISTOPAQUE® 1119
Red blood cells
Figure 9: Sequence of tube contents during isolation of rat neutrophils
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All layers to within 0.5 cm of the granulocyte layer were aspirated off, and 
granulocytes were then transferred to a fresh 50 ml tube. PBS containing 0.2 % 
(w/v) glucose was then added to 50 ml, and the cells spun at 300 x g for 10 min. 
The supernatant was removed and the cell pellet resuspended in 7.5 ml ice-cold 0.2 
% (w/v) NaCl. After mixing for 1 min, 7.5 ml ice-cold 1.6 % (w/v) NaCl was 
added. PBS (with 0.2 % (w/v) glucose) was added to 50 ml and cells spun at 200 x 
g for 10 min. This was repeated twice, and the cell pellet resuspended in IX PBS 
(with 0.2 % (w/v) glucose) or the required assay buffer (see TablelO).
2.8 -  Wool column purification of human T cells
PBMC were prepared as described in section 2.2.1. The final PBMC pellet was 
resuspended in 2 ml RPMI-1640 medium (SIGMA) with 2 mM glutamine 
(SIGMA) and 5 % (v/v) human AB serum (SIGMA).
2.8.1 -  Preparation of wool column
Columns were prepared by placing 6 g of teased out nylon wool (Robbins 
Scientific, Cheshire, UK) into a 10 ml syringe and autoclaving the whole column. 
Prior to use the wool column was soaked in 10 ml of RPMI-1640 medium with 5 % 
(v/v) human AB serum. After allowing the medium to flow through, and ensuring 
the wool was thoroughly soaked, the bottom of the column was stoppered, and then 
placed in an incubator at 37 °C for 5 min in order to pre-warm the column.
2.8.2 -  Isolation of T-cells
Freshly prepared PBMCs were added to the column after the stopper was removed. 
Once the PBMC fraction had flowed through the nylon wool matrix, the stopper 
was replaced and the column incubated for 1 hr at 37 °C in an incubator. The
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bottom stopper was removed and 20 ml of RPMI-1640 medium was added 
dropwise to the column and the effluent containing purified T cells were collected 
into a 50 ml centrifuge tube. The cells were then counted on a Coulter counter, 
spun down and resuspended in RPMI-1640 medium (without serum) at 5 x 10^  
cells/ml.
2.9 -  Jurkat J6 and HL-60 cells
2.9.1 - Routine cell culture
Cells were maintained in 1 X RPMI 1640 (with L-glutamine and 25 mM HEPES) 
(GIBCOBRL), 10 % (v/v) fetal bovine serum (SIGMA) and 1 % (v/v) penicillin 
/streptomycin (SIGMA). The cells were incubated at 37° C in a humid atmosphere 
containing 5% CO2. A cell stock was preserved at all times in 10 ml of medium in 
a 25 cm  ^flask. Fresh aliquots from frozen stocks of Jurkat J6 and HL-60 cells were 
routinely thawed at 4-week intervals, to avoid any decline in function with time.
2.9.2 - Freezing and thawing cells
0.9 ml of cells at ~ 40% confluency were aliquoted into cryotubes. The tubes were 
kept on ice for 15 min, after which 0.9 ml freezing medium (see section 2.1.3) was 
placed into each cryotube. The tubes were then kept at -  80 °C for 3 days, after 
which they were stored in liquid N2 (-120 °C to -130 °C).
2.9.3 - Cell passaging
Cells were passaged every 2 - 3  days by resuspending in warm (37° C) medium, at 
1:10-1:40 dilutions. Cells in stock flask were always kept at ~ 50% confluency.
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2.10 -  Isolation of total RNA from immune cells
Total RNA was isolated using PURESCRIPT® RNA isolation kit (CENTRA). 
Table 2: List of reagents used to isolate RNA
REAGENTS COMPONENTS
Cell Lysis Solution Citric acid, EDTA, SDS (proprietary 
formulation)
Protein-DNA-Precipitation Solution Citric acid, sodium chloride (proprietary 
formulation)
Diethylpyrocarbonate (DEPC) treated 
water
1 ml DEPC added to 1 L double distilled 
water. Solution mixed in a fume hood 
and then autoclaved.
3 ml of isolated PBMCs or cultured cells were added to an Oak Ridge centrifuge 
tube and centrifuged at 15,000 x g for 1 min. The supernatant was removed leaving 
behind a visible white cell pellet and 100 -  200 pi of residual liquid. The tube was 
vortexed vigorously to resuspend the cells, which greatly facilitates cell lysis. 3 ml 
Cell Lysis Solution was then added to the tube and pipetted up and down 3 times to 
lyse the cells.
1 ml Protein-DNA Precipitation Solution was added to the cell lysate, and the tube 
inverted gently 10 times and placed on an ice bath for 10 min. This was then 
centrifuged at 15, 000 x g for 5 min. The precipitated proteins and DNA formed an 
irregular brown pellet.
The supernatant containing the RNA was pipetted off and transferred into a clean 
Oak Ridge centrifuge tube containing 3 ml 100% isopropanol (BDH). The sample 
was mixed by inverting gently 50 times and centrifuged at 15, 000 x g for 5 min.
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At this point the RNA became visible as a small translucent pellet. The supernatant 
was poured off and the tube was inverted and drained on clean absorbent paper.
3 ml of 70% (v/v) ethanol was added and the tube inverted several times to wash 
the RNA pellet. This was then centrifuged at 15,000 X g for 2 min and the ethanol 
poured off. The tube was inverted and drained on clean absorbent paper and air 
dried for 15 min.
To hydrate the RNA pellet, 100 pi of DEPC-treated water was added. The RNA 
was allowed to rehydrate on ice for at least 30 min, and then vortexed vigorously 
for 5 seconds, pulse spun and carefully transferred to a 1.5 ml microcentrifiige tube. 
The sample was stored at -  70° C to -  80° C until use.
Before use the sample was vortexed vigorously for 5 seconds and pulse spun. The 
sample was pipetted up and down several times to ensure adequate mixing. From 
this isolated procedure approximately 2-7 pg/ml of RNA from whole blood was 
obtained.
2.11 -Measurement of RNA concentrations
The concentration and purity of total RNA isolated was determined by measuring 
the absorbance at 260 nm (A260) and 280 nm (A280) in a spectrophotometer. 
Absorbance readings at 260 nm measure RNA concentration and should be greater 
than 0.15 to ensure significance.
The concentration was calculated using the equation:
[RNA] pg/ml = Absorbance26o x 40 x dilution factor
where *40* corresponds to 40 pg/ml of RNA per 1 unit of absorbance at 260 
nm.
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This relationship is valid for measurements in water. Therefore to measure RNA 
concentrations spectrophotometrically, the samples were diluted in DEPC-treated 
water.
2.12- Assessment of RNA Purity
The ratio between the readings taken at 260 nm and 280 nm (A260 / A280) 
provided an estimate of the purity of RNA. The A260 / A280 ratio is influenced by 
pH. As water is unbuffered, the same RNA sample may show different A260/A280 
ratio in different types of water, ranging from 1.5-1.9. Also, the addition of the 
RNA itself influences the pH of the water. Therefore, in order to determine the 
A260 / A280 ratios samples were diluted in 10 mM Tris-Cl, pH 7.5. Pure RNA has 
an A260 / A280 ratio of 1.8-2.1 in 10 mM Tris-Cl, pH 7.5. All samples used in 
these experiments had an A260/A280 ratio of at least 1.8.
2.13 -  Agarose gel electrophoresis of RNA
The integrity of the isolated total RNA was checked by non-denaturing agarose gel 
electrophoresis. A 0.8 % (w/v) agarose gel with ethidium bromide (0.7 pg/ml) was 
prepared in RNAase free 1 X TAB buffer. The gel cast, comb and tank were 
treated overnight with 1 % (v/v) H2O2 prepared in DEPC-treated water, and washed 
with DEPC-treated water. The RNA sample was prepared in Promega 6 X dye 
used only for RNA. The gel was run at 80 V for 2 hours and visualised under 
ultraviolet illumination.
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2.14 -  Purification of mRNA
Poly (A)^ RNA was isolated using Dynabeads® oligo (dT)^  ^ magnetic beads 
(DYNAL), 2.8 pm in diameter, with a 25 nucleotide long chain of 
deoxythymidylate attached covalently to the bead surface via a 5' linker group. 
Beads were stored in PBS containing 0.02 % (v/v) NaNg. 0.2 ml (1 mg) of bead 
suspension was pipetted into a 1.5 ml microcentrifuge tube, which was placed into a 
Dynal MPC®-E magnetic particle concentrator, and the supernatant removed. The 
beads were washed by the addition and removal of 100 pi 2X binding buffer (20 
mM Tris-Cl, pH 7.5; 1 M LiCl; 2 mM EDTA). 100 pg total RNA was resuspended 
in 10 mM Tris-HCl (pH 7.5) and heated for 2 min at 65°C to disrupt the secondary 
structures. This was then added to the washed beads and mixed thoroughly by 
placing on a rotating platform for 3 -  5 min at room temperature. This allows the 
mRNA to anneal to the beads. The tube was then placed on the magnet to allow 
removal of the supernatant. The beads were washed twice with 200 pi of washing 
buffer (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl, 1 mM EDTA) and resuspended in 
10 pi 10 mM Tris-HCl before heating at 65°C for 2 min. This was then placed on 
the magnet again so eluted poly (A)^ RNA could be transferred to a new RNase- 
free tube.
2.15 -  cDNA Synthesis
Poly (A)^ RNA was reverse transcribed into cDNA using SUPERSCRIPT™ II 
RNase H Reverse Transcriptase enzyme, a recombinant reverse transcriptase from 
Moloney Murine Leukaemia Virus (M-MLY) lacking RNaseH activity (Gibco-Life 
Technologies).
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Table 3: List of reagents used to synthesise first strand cDNA
REAGENTS COMPONENTS
5X First Strand Buffer 250 mM Tris-HCl, pH 8.3; 375mM KCI, 15mM MgCb
DTT 100 mM
dNTPs 10 mM (10 mM each dATP, dOTP, dTTP, dCTP neutral pH)
Superscript^'^ II RNase H 
Reverse Transcriptase 
buffer
20 mM Tris-HCl (pH 7.5); 100 mM NaCl; 0.1 mM EDTA; 





20 mM Tris-HCl (pH 8.0); 50 mM KCI; 0.5 mM EDTA; 8 mM 
DTT; 50% (v/v) glycerol
(RNaseOUT^*^) 40 units/pl
E.coli RNase H 2 units/pl
To 10 jxl of eluted mRNA, l|al of oligo dT, 1 1^ of 10 mM dNTPs, and 1 i^l of RNA 
free water were added, the mixture heated to 65 °C for 5 min and quick chilled on 
ice. 4 pi of 5X First Strand Buffer, 2 pi of DTT and 1 pi RNaseOUT"^  ^
Recombinant Ribonuclease Inhibitor were added to the previous mix and the tube 
incubated at 42°C for 2 min. 1 pi of Superscript^^ was then added and mixed by 
pipetting gently up and down and the reverse transcription was allowed to proceed 
at 42°C for 50 min in a thermocycler. The reaction was inactivated by heating at 
70°C for 15 min. Any remaining RNA was removed by adding 1 pi of E.Coli 
RNase H and incubating at 37°C for 20 min. The final product was stored at -  
20°C before being used for PCR.
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2.16 -  Reverse Transcription-Polymerase Chain Reaction
The Expand High Fidelity PCR system from Roche was used to amplify cDNA 
from human brain, human PBMC and Jurkat J6 cells. This is composed of an 
enzyme mix containing thermostable Taq DNA polymerase and a proofreading 
polymerase. For a single reaction the following components were added to a thin- 
walled PCR tube:
Table 4: List of reagents used per tube in RT-PCR
Reagents Components Volume (pi)
Sterile dd H2O - 34.60
Expand High Fidelity 
Buffer
lOX, with 15 mM MgCb 5
dNTP mix 2 mM (2 mM each dATP, dGTP, dTTP, 
dCTP at neutral pH)
7.5
cDNA 5 - 1 0  ng/ml 1
Forward primer 20 pM 0.75
Reverse primer 20 pM 0.75
Expand High Fidelity PCR 
system, Enzyme mix
20 mM Tris-HCl, pH 7.5, 100 mM KCI, 
ImM DTT, 0.1 mM EDTA, 0.5% 
Tween-20 (v/v), 0.5% Nonidet P40 (v/v), 
50% glycerol (v/v).
Taq DNA polymerase, proofreading 
polymerase (3.5 x 10^  units/ml)
0.40
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2.17 -  Sensitivity and specificity of TaqMan assay
To confirm the PCR results quantitatively, real-time TaqMan RT-PCR was 
performed on a range of human tissues in which 18 S RNA was used as an 
endogenous control. By using an endogenous control as an active reference, 
quantitation of an mRNA target can be normalised for differences in the amount of 
total RNA added to each reaction. However, as 18S RNA is a ribosomal RNA 
species it may not always represent the overall cellular mRNA population. Despite 
this, it is one of the most commonly used normalisers and was therefore used as the 
active reference in the TaqMan experiments.
Serial dilutions (10 fold) of control RNA (brain, placenta, testis mix) from 1/10 to 
1/10  ^were performed to test the sensitivity of the assay. 18S rRNA was used as an 
internal standard in the real-time quantification of mRNA levels in the samples 
studied. The fluorochrome dye VIC was used to label the probe used for 18S, 
which is preferred for use with F AM (the reporter dye), as F AM and VIC have the 
largest difference in emission maximum (Dorak, 2000; Grove, 1999).
The 18S rRNA primer/probe set effectively amplified all cDNAs as expected 
(Figure 10). This showed that all samples in the wells contained a sufficient 
amount of RNA to be detected by the sequence detector. Human brain cDNA was 
amplified between cycles 9 - 1 0  indicating high levels of amplification. The no 
template control showed amplification of products very late at cycle 36, which 
indicates the absence of amplification (Figure lOA).
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Figure 10: Amplification plot (A) and  s tan d a rd  curve (B) from TaqMan RT-PCR using 
th e  18S rRNA probe and  prim er se t. In A, th e  norm alised  repo rter dye em ission  
(ARn) is plotted ag a in st the  cycle num ber. S am ples show n to  amplify betw een 
cyc les 10-12 w ere cDNA obtained  from  a variety of hum an tis su e s , including hum an 
brain and a range of hum an im m une cells. All sam p les  w ere p resen t a s  d u p lica tes  in 
th e  96-well plate, th e  am plification p lo ts of w hich are rep resen ted  a s  pairs of 
co lours. Only sam p les  of in terest have been labelled. S am ples show n to  amplify 
betw een cycles 14-18 are cDNA from  tw o sep a ra te  s e ts  of hum an PBMC ( and
sky blue plots), while sam p les  show ing  am plification betw een cycles 24-29 are cDNA 
obtained  from hum an neutrophils (blue and pink). The no tem plate control (blue and 
green) sh o w s am plification signals  betw een cyc les 33-34. In B, the  s tan d ard  curve 
(cDNA obtained  from a mix of hum an brain, p lacen ta  and  tes tis) sh o w s th e  Ct values 
from  each  of the  p lots in A plotted ag a in s t th e  relative rRNA copy num bers.
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2.18 -  Primers designed for RT-PCR
Table 5: Primers designed for the amplification of GABAa receptor subunit mRNAs. Nucleotide positions 
of primers within the cDNA sequence are shown. The internal' primers are nested within the external' 
primers. This is t)ecause the PCR product obtained using the external' primers was used as a template 
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Table 6: Primers designed for the amplification of glycine receptor 
subunit mRNAs.
Glycine External External Internal Internal
Receptor Forward Reverse Forward Reverse
subunit Primer Primer Primer Primer
(5’-3 ’) (S’- 3’) (5’-3’) (S’- 3’)
a l ‘"*GGCAAC ^^ •^^ CGATCTT ^^*GGATGA i46»g g t g GTG
ATAAGGAG CTTGGCCCT AGCTGGAG TTACTGTTG
CTGC‘” ‘ çj'yl528 AAGGC'^^ ^ TTGG*^ ®^
a2 ""TCCAGG 162»c g GTCCA *^^AGGAAG i5»5t t g t GGG
CAACACAA CAAACTTCT AAGACGTT AGTGGGTTG
g g a g ‘‘'“ ACTCG*^ *^ Gc 1567
(x3 ' ““ a c t t c t 1665GGTATCA ^^ "^ AGGGAA 16J1TTCCTCA
GAGATTTC ATCTTCTTG AGCCGATTC TTTCATCAG
g a c g '""' q q 164S AGC*^ '^ GAC^ '^^
p "^ ■’g a a t t g *^ ^^ GGGGAGG '^ "^"GAATGG "^CCATAGC
CTAAGGCT CTTCTTGTTG AACAGGGA AGTCATAAT
GAGC"” jU39 TGGA* ”^^^
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2.19 -  Primers and probes designed for TaqMan RT- PCR
All primers and probes for TaqMan RT-PCR were purchased from Applied 
Biosystems, Perkin-Elmer.
T able 7: P rim ers an d  p ro b e s  d e s ig n e d  fo r GABAa an d  g iycine re cep to r su b u n it 
mRNAs. T he forw ard an d  rev e rse  p rim ers w ere  d e s ig n e d  a s  c io se  a s  p o ss ib ie  to  th e  
p ro b e  w ithou t overiapp ing  th e  p ro b e . N ucleo tide p o s itio n s  a re  sh o w n  on  e ith e r s id e  
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2.20 -  Agarose gel electrophoresis
Agarose gels for DNA analysis were made by the addition of 1.5 -  2% (w/v) 
agarose to 1 x TBE buffer. Heating in a microwave oven at 40 % power dissolved 
the agarose. Visualisation of DNA was achieved by the addition of 5 pg/ml 
ethidium bromide to this solution. Gels were poured in a gel cast with a comb and 
allowed to set before running in a IX TBE buffer, in a horizontal gel apparatus at 
100 V. DNA samples were loaded with 6X loading dye (26 % (v/v) H2O; 50 % 
(v/v) glycerol; 21 % (v/v) 0.05 M EDTA; 0.1 % (w/v) bromophenol blue; 0.1 % 
(w/v) xylene cyanol). To determine the size of bands 100 bp (NEB) and 1 Kb 
(Promega) molecular weight markers were used.
2.21 -  Purification of DNA from agarose gels
The QIAquick Gel Extraction Kit (QIAGEN) was used to purify DNA from 
agarose gels. This allows the extraction and purification of DNA from 100 bp to 10 
Kb out of agarose gels in TBE buffer. In high salt conditions the silica-membrane 
contained on spin-columns absorbs the DNA, while contaminants pass through the 
column. All the centrifugation steps were performed at 13000 X g.
The DNA band was excised and weighed in a 1.5 ml microcentrifuge tube. 3 
volumes of buffer QG were added to the tube, and incubated at 50 °C for 10 min (or 
until the gel slice had completely dissolved). 1 gel volume of isopropanol was then 
added to the sample, mixed and applied to a QIAquick column and centrifuged for 
1 min. The flow-through was discarded, and the column replaced in the same 
collection tube. To remove all traces of agarose, a Anther 0.5ml of Buffer QG was 
added to the column, spun for 1 min and the flow-through discarded. To wash, 0.75 
ml of Buffer PE was added to the column, left to stand for 2 -  5 min and then spun 
for 1 min. The flow-through was discarded and the column centrifuged for an 
additional minute. The QIAquick column was then placed into a clean 1.5 ml
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microcentrifuge tube. To elute the DNA 30 pi of Buffer EB was added directly to 
the centre of the QIAquick membrane, left to stand for 1 min and then centrifuged 
for 1 min. The eluted DNA was stored at -  20°C.
2.22 -  Cloning of PCR products
PCR products were cloned into the vector pCR®- Blunt II vector using the Zero 
Blunt™ PCR cloning kit (Invitrogen). The TOPO® vector was supplied linearised. 
The ligation mix consisted of 1 pi of the vector, ~ 4 pg/pl PCR product, 1 pi salt 
solution (1.2 M NaCl, 0.06 M MgCli) and 0.5 pi sterile water. This was incubated 
for 5 minutes at room temperature. 50pl (one vial) of cells was used per 
transformation. After the vial containing the One Shot™ TOP 10 competent cells 
was thawed on ice, 2pl of the recombinant plasmids were added. This was gently 
mixed and incubated on ice for 5 -  30 min. Cells were then heat shocked for 30 sec 
in a 42° C water bath followed by immediate transfer to ice for 2 min. 250pl of 
SOC medium (at room temperature) was added to the cells before placing the tubes 
in a horizontal shaker for 1 hour at 37° C. 50, 100 and 150pl of the transformation 
mix were spread on to prewarmed LB agar plates containing 50pg/ml kanamycin 
and these were incubated at 37° C overnight. Colonies were picked and grown for 
1 2 - 1 6  hours in LB medium containing 50 pg/ml kanamycin and plasmid DNA 
was purified from the bacteria using the CONCER'P^ Rapid Plasmid Purification 
System (Life Technologies, Gibco BRL®). This DNA was analysed initially by 
restriction digestion and then sequencing.
2.23 -  Small scale preparation of plasmid DNA
The alkaline lysis method from the CONCERT^^ Rapid Plasmid Purification 
System (Life Technologies, Gibco BRL®) was used to isolate plasmid DNA from 
bacterial cultures. 3 ml of an overnight culture was centrifuged at 12000 x g for 2 
min and all medium removed. The resulting pellet was resuspended in 210 pi of
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buffer G1 (containing RNase A) to form a homogenous solution. 210 |il of solution 
G2 was added and mixed by inversion before incubation at room temperature for 5 
min to produce a clear solution. 280 pi of G3 buffer was added and the solution 
mixed by inversion before centrifugation of samples at 12,000 x g for 10 min. The 
resulting supernatant was placed into a spin cartridge, containing silica-based 
membranes where the plasmid DNA is selectively adsorbed, which was contained 
in a 2 ml wash tube. Following removal of the flow-through the column was 
washed with 500 pi of buffer GX followed by a wash with 700 pi of buffer G4 
(containing 95 -  100 % ethanol) at 12000 x g for 1 min. DNA was eluted by the 
addition of 75 pi of TE buffer, incubation for 1 min at room temperature and then 
final centrifugation at 12000 x g for 2 min.
Table 8: List of reagents used for preparing plasmid DNA
REAGENTS COMPONENTS
Cell suspension Buffer (Gl) 50 mM Tris-HCl, pH 8.0; 10 mM EDTA
RNaseA 20 mg/ml in water
Cell Lysis solution (G2) 200 mM NaOH, 1 % (w/v) SDS
Neutralisation Buffer (M3) Acetate and guanidine hydrochloride, 
(proprietary formulation)
Wash Buffer (GX) Acetate, guanidine hydrochloride, 
EDTA, ethanol (proprietary formulation)
Wash Buffer (G4) NaCl, EDTA and Tris-HCl, pH 8.0 
(proprietary formulation)
TE Buffer (TE) 10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA
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2.24 -  Endonuclease restriction of DNA
DNA samples of 1 -  5 pg were digested with one or two restriction enzymes (10-20 
units) in the reaction buffer (4 pi) recommended by the manufacturer. Sterile water 
was added to a volume of 40 pi and the reaction incubated at 37°C for 1 -  4 hours.
2.25 -  Sequencing of clones and sequence analysis
Approximately 250 ng of DNA preparation was mixed with 10 pmol of primer in 6 
pi of double distilled water and sent for sequencing at the University of Bath DNA 
Autosequencing Service. The primers used for sequencing the cloned products in 
pCR®-Blunt vector were the M l3 forward and M l3 reverse from Invitrogen. 
Sequence analysis was carried out on the GCG (Genetic Computer Group, 
Wisconsin, USA) suite of programs, accessible via the gnome and elf workstations, 
for analysis and comparison with existing sequences in the database.
2.26 -  Preparation of rat brain membranes
Sprague-Dawley rat brains were rapidly removed and homogenised in 20 ml/g 
original weight of ice-cold 10 % (w/v) 0.32M sucrose, pH 7.4 (containing ImM 
EDTA, 0.1 mM PMSF and 0.01 % (w/v) NaNg). The whole homogenate was 
centrifuged at 1000 x g for 10 min. Supernatant (SI) was decanted and retained on 
ice, while pellet (PI) was resuspended in 5 ml/g original weight in ice cold 0.32 M 
sucrose and centrifuged at 1000 x g for 10 min. Supernatant (S2) was then 
combined with SI and centrifuged at 12,000 x g for 30 min. The pellet (P2) was 
resuspended in 2.5 ml/g original weight in ice-cold 50mM phosphate buffer (80 
mM K2PO4 , 20 mM KH2PO4 , pH 7.4), containing 1 mM EDTA, 1 mM PMSF and 
0.1 % (w/v) NaNg. This was washed 2 times by centrifugation at 12,000 x g for 30 
min. The washed pellet was then resuspended in 2.5 ml/g original weight in ice-
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cold 50 mM phosphate buffer containing 1 mM EDTA, 1 mM PMSF and 0.1 % 
(w/v) NaNg. The suspension was divided into 5 ml aliquots and stored at -  20°C 
for up to 3 months. ,
2.27 -  Preparation of PBMC, Jurkat J6 and HL-60 and HÉK- 
293 cell membranes
Jurkat J6, HL-60 cells and HEK-293 cells were grown to 50 % confluency and 
harvested at 500 x g for 5 min. The cell pellets were resuspended and washed three 
times in ice-cold PBS with 1 mM EDTA and protease inhibitor. Isolated human 
PBMC were harvested at 300 x g for 5 min.
The pellets were resuspended in 10 ml ice-cold IX PBS with 1 mM EDTA and 
protease inhibitor and 0.1 % (w/v) sodium azide. The cells were homogenised 
using a sonicator (3 x 15 s pulses) and then transferred to a 10 ml Oak Ridge 
ultracentrifuge tube. Samples were centrifuged at 12,000 x g for 30 min at 4°C. 
The pellet was resuspended and centrifuged for a further 20 min at 12,000 x g at 
4°C. The supernatant was discarded and the cell pellet resuspended in 1 -  2 ml ice- 
cold IX PBS with 1 mM EDTA, 1 mM PMSF and 0.1 % (w/v) sodium azide. 
Samples were stored at -  20°C.
2.28 -  Preparation of cell lysates
Isolated human T-cells, human neutrophils and BaF13 cells were harvested at 300 x 
g for 5 min. The cell pellet was resuspended in 5 ml ice-cold 1 X PBS with 1 mM 
EDTA, 1 mM PMSF and 0.1 % (w/v) sodium azide. The cells were homogenized 
with a sonicator (3 x 15 s pulses). Samples were stored at -  20°C.
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2.29 -  Protein Quantitation
The Coomassie® Plus Protein Assay Reagent Kit (PIERCE) was used for total 
protein quantitation. The method of protein detection is based on the Bradford 
method (Bradford, 1976). The reagent contains: Coomassie dye, methanol,
phosphoric acid and solubilizing agents in water. Microwell plates were used and 
15 pi of sample or standard (BSA provided with the kit) were added per well plus 
300 pi of Coomassie® reagent. Plates were mixed on a shaker for 30 sec and the 
absorbance was measured at 595 nm. A standard curve was prepared by plotting 
the average blank corrected 595 nm reading for each BSA standard, versus its 
concentration in pg/ml. This curve was used to determine the protein concentration 
of each unknown sample.
2.30 -  SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Table 9: List of reagents used for SDS-PAGE
REAGENTS COMPONENTS
30 % Acrylamide mix 30 % (w/v) acrylamide, 0.8 % (w/v) bis acrylamide
IX Tris-HCl, pH 8 . 8 1.5 M Tris-HCl (stored at 4°C)
IX Tris-HCl, pH 6 . 8 0.5 M Tris-HCl (stored at 4°C)
SDS 1 0 % (w/v) sodium dodecyl sulphate
APS 1 0 % (w/v) ammonium persulphate in dd H2O
6 X SDS Loading Buffer 0.35 M Tris-HCl, pH 6 .8 ; 10.28 % (w/v) SDS; 36 % (v/v) 
glycerol; 5 % (v/v) P-mercaptoethanol; 0.012 % (w/v) 
bromophenol blue (stored at - 20°C)
5X Running Buffer 3 g Tris-base, 14.4 g glycine and 0.5 g SDS in 100 ml o f dd 
H2O
Coomasie Blue Solution 50 % (v/v) methanol, 0.05 % (w.v) Coomasie Brilliant Blue 
R, 10 % (v/v) acetic acid in dd H2O (Coomasie Brilliant 
Blue R was dissolved in methanol before adding acetic acid 
and water)
Destaining Solution 5 % methanol (v/v), 7 % (v/v) acetic acid in ddH2 0
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For the preparation of two 8 % (w/v) separating gels, 2.7 ml 30 % acrylamide mix 
(SIGMA) were combined with 4.6 ml dd H2O, 2.5 ml 1.5 M Tris-HCl (pH 8.8), 
100 pi 10 % (w/v) SDS (SIGMA), 100 pi 10 % (w/v) APS (Life Technologies) and 
6 pi of TEMED (SIGMA). Using a 5 ml pipette the solution was transferred to 
Atto^“ mini-gel rigs, overlaid with isopropanol and allowed to polymerise at room 
temperature. When the gels were ready the solvent was removed and the gel 
interface rinsed with distilled H2O. A 5 % (w/v) stacking gel was prepared by 
mixing 0.83 ml of 30 % acrylamide mix, 3.4 ml of dd H2O, 0.63 ml of I M Tris-Cl, 
50 pi 10 % (w/v) SDS, 50 pi 10 % (w/v) APS and 5 pi TEMED. The solution was 
pipetted over the separating gels and the combs inserted while the gel was allowed 
to set.
Gels were placed into an electrophoretic chamber and IX running buffer was 
added. Combs were removed and wells washed out with buffer. Samples were 
prepared by resuspension in 6X SDS loading buffer and denatured by incubation in 
a boiling water bath for 5 min and spun down at 12000 x g for 3 min immediately 
prior to loading onto the gel.
Gels were run at 100 V until the dye front reached the bottom of the gel. Gels were 
stained by soaking and rotating in Coomasie Blue solution for 10 minutes and 
destained with 3 washes in destaining solution until background staining was 
removed.
2.31 -  Western Blotting
2.31.1 -  Semi-dry blotting
Two gel sized sets of 2 sheets of extra thick filter paper (Bio-Rad) were soaked for 
30 min in transfer buffer (25 mM Tris-HCl pH 8.3, 150 mM glycine, 0.037 % 
(w/v) SDS and 20 % (v/v) ethanol added (immediately before use). The first set 
was aligned on the graphite transfer plate of a NovaBlot blotter (Pharmacia)
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followed by a nitrocellulose membrane (Amersham), previously rinsed in dd H2O 
and in transfer buffer. The SDS-PAGE gel was rinsed in water and in transfer 
buffer and rolled out on top of the membrane. The stack was overlaid with the 
second set of soaked filter papers and any air bubbles between layers, were 
removed by rolling a glass pasteur pipette over the top of the sandwich. The upper 
graphite plate was put on the top and the rig connected to the power supply set at 
0.8 mA/cm^ of gel for 1 hour.
2.31.2 -  Wet blotting
Two gel sized (9 cm x 6 cm) sheets of extra thick filter paper (Bio Rad) were 
soaked for 15 min in transfer buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 20 
% methanol). A mini trans-blot cell and module (Bio Rad) was used for the 
transfer of proteins from the gel matrix onto nitrocellulose membrane (Life 
Sciences). A presoaked fiber pad was aligned onto one of the two plates of the gel 
holder cassette. A piece of pre-soaked filter paper was then placed upon this, upon 
which first the gel and then the membrane were aligned. A second piece of pre­
soaked filter paper was placed on top and a 1 ml gleiss pipette was rolled over the 
top to removed any air bubbles. To complete the sandwich, a second pre-soaked 
fiber pad was placed on top and the cassette was firmly clamped. The cassette was 
placed inside the transfer cell, with the gel side facing the negative electrode, and 
this was then placed inside the tank. In order to regulate temperature a Bio-ice 
cooling unit was also placed inside the tank. The apparatus was then set up to run 
at a constant current of 30 mA at 4 °C overnight, or at 100 mA at 18 °C for 2 
hours.
2.32 -  Chromogenic substrate detection
The nitrocellulose membrane was incubated overnight at 4 °C in blocking solution 
(2 % (w/v) glycine, 5 % (w/v) MarveF"  ^ non-fat milk powder in PBS with 0.1 % 
(v/v) Tween). The blot was washed in PBS/Tween 2 times and incubated for 2 -  3
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hours at room temperature in primary antibody diluted 1:1000 in PBS/Tween.. To 
remove unbound antibody, the membrane was washed in PBS/Tween for 5 min, 10 
min and 15 min on a rotating table. The VECT AST AIN® ABC kit (Vector 
Laboratories) was used to detect immunoreactivity in the blot. Upon removal of 
primary antibody, the membrane was incubated for 1 hr at room temperature in the 
biotinylated secondary antibody diluted 1:1000 in PBS/Tween. At the same time 
Avidin DH and biotinylated horseradish peroxidase were each diluted 1:500 in 
PBS/Tween (ABC reagent), and mixed on a rotating table for 1 hour at room 
temperature. Unbound secondary antibody was removed by washing in 
PBS/Tween 2 times, and the blot was then incubated in the ABC reagent for 1 hour 
at room temperature. This was then washed in PBS/Tween 2 times and in IX PBS 
2 times before applying the chromogenic substrate (2 ml 4-chloro-1 -napthol, 10 ml 
PBS (IX) and 5 pi 30 % H2O2. 1 ml added per lane). To stop the reaction, the blot 
was washed in IX PBS 2 times and then with copious amounts of dd H2O) to 
remove the peroxidase. The membrane was then dried between two pieces of 
Grade 1 filter paper (Whatman).
2.33 -  Preparation of coverslips and fixation of cells
Coverslips were treated with 1 % (w/v) PEI solution to allow cells to stick to the 
surface. A 10 % (w/v) stock solution of PEI was prepared by adding 1 g of PEI to 
9 ml dd H2O and dissolved for 2 hours at 37° C. In the fiime hood this was then 
sterilised with a 0.22 pm filter. For experiments, 100 pi of the PEI stock solution 
was dissolved in 10 ml, 100 mM borax buffer (pH 8.3). 0.5 -  2 ml was used on
the coverslip and left for 3 hours -  overnight at 37 °C. To remove excess PEI the 
coverslips were then washed 3 times with 3 ml PBS.
Jurkat cells (50 -  70 % confluency) were transferred to 50 ml falcon tubes and 
centrifuged at 400 x g, 15 °C for 5 min. The medium was aspirated and cells 
resuspended in 30 ml PBS. 0.5 -  2 ml of the cell suspension was pipetted over the 
treated coverslips and incubated at room temperature for 20 -  30 min. Excess cell
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suspension was removed by aspiration and the coverslips washed 3 times in 2 -  3 
ml IX PBS.
To fix cells 2 ml 4% PFA/PBS was added to the coverslips and left at room 
temperature for 20 min. Alternatively, ice-cold methanol was added to the 
coverslips and incubated at -  20 °C for 5 min. The coverslips were then washed 3 
times in 2 -  3 ml IX PBS. To minimise non-specific adsorption of antibody to the 
cells, 1 % BSA/PBS or 1 % FBS/PBS was used as blocking buffer. Coverslips 
were covered with 35 -  50 pi blocking buffer for 10 -  15 min at room temperature.
2.34 -  Antibody staining
The primary antibody was diluted (1 in 100) in either the medium or the blocking 
buffer. Once excess blocking buffer was aspirated off, the coverslips were inverted 
onto 70 -  80 pi of primary antibody mix for 1 hr or more at room temperature. The 
mix consisted of a 1:100 dilution of a CD marker mouse anti-human antibody IgG 
(Serotec) and a 1:100 dilution of GABAa a l  rabbit anti-bovine antibody (a gift 
from Prof. Anne Stephenson, London School of Pharmacy). Unbound antibody 
was removed with two 5 min washes in blocking buffer and then two 5 min washes 
in PBS.
To bind secondary antibody, coverslips were inverted onto 70 pi of the secondary 
antibody mix (a 1:100 dilution of FITC conjugated anti-rabbit IgG secondary serum 
(SIGMA) and a 1:100 dilution of Texas Red conjugated anti-mouse IgG secondary 
serum (SIGMA). This was left for 20 min at room temperature in the dark and 
then, keeping the dish covered, washed twice, 5 min each with blocking buffer. 
Coverslips were then washed another 2 times, 5 min each with PBS.
The coverslips were mounted onto microscope slides using 15 -  20 pi of Mowiol, 
placed in the dark and allowed to dry overnight. The slides were examined under a 
Zeiss LSM 510 confocal fitted to an inverted Axiovert 100 M microscope, using a
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helium neon laser and FITC and rhodamine filter set. Negative controls for 
immunostaining were set up in parallel in the presence of secondary antibody only.
2.35 -  Loading immune cells with FLU0-3AM, a fluorescent 
Ca *^ indicator
Jurkat and HL-60 cells in RPMI 1640 medium, or isolated PBMCs or neutrophils 
in IX PBS (with 0.2 % (w/v) glucose), were centrifuged at 300 x g at room 
temperature for 5 min. The supernatant was aspirated and cells resuspended in 10 -  
15 ml mHBSS assay buffer (Table 10). After being centrifuged again at 300 x g at 
room temperature for 5 min, the cells were resuspended in 5 ml mHBSS buffer. To 
load the cells, 5 pM FLUO-3AM was added to the cell suspension, which was then 
left on a roller at room temperature for 90 min.
FLUO-3AM loaded cells were centrifuged at 300 x g for 5 min, the supernatant 
discarded, and the cells resuspended in assay buffer to a concentration of 4 x 10^  
cells/ml (for studies using the FLIPR) or Ix 10^  cells/ml (for studies using the 
FACS).











Serum (rat or human) 0.1%
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2.36 -  Investigating [Ca^ i^ in human neutrophils using the 
Fluorescent Imaging Plate Reader (FLIPR)
2.36.1 -  Estimation of fMLP and LPS working concentrations
In order to determine which concentration of agonists would give the maximal 
response, fMLP and LPS were exposed to loaded human neutrophils at eleven 
different concentrations. fMLP was investigated at concentrations ranging from 1 
pM to 0.1 nM , and LPS from 1 mg/ml to 1 ng/ml.
2.36.2 -  Addition of agonists and GABA or glycine to neutrophils
The assay was performed in 96-well Poly-o-Lysine coated black plates (Becton 
Dickinson). To each well, 50 pi of cells was added to give 200,000 cells/well. 50 
pi of test compound or vehicle was added to the wells at 2X final concentration. 
The plates were then centrifuged at approximately 200 x g for 5 min and then 
incubated at room temperature for 30 min. Calcium transients in response to 
agonists and antagonists were measured using a FLIPR. Fluorescence readings 
were taken every 2 seconds for a total run time of 2 min. Cells were excited at 488 
nm, and emission readings taken at 525 nm. 50 pi of agonist at 3X final 
concentration was added after 10 seconds. The assay plate conditions are 
summarised below:
A 96-well plate was prepared containing 200,000 cells/well and 50 pi of vehicle 
(buffer) or test compound. A baseline fluorescence determination was made, and 
50 pi of 1 nM fMLP or 1 mg/ml LPS was added after 10 seconds. Fluorescence 
data were collected over 2 min. GABA or glycine were then added at 2X final 
concentration, in 0.5 log dilutions, with the highest final concentration for GABA 
and glycine at 3 mM. Fluorescence data were once again collected over 2 min.
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Responses to agonists and treatment with G ABA or glycine were measured as 
arbitrary fluorescence units and were calculated by taking the difference between 
the maximum response and the minimum.
2.37 -  Investigating [Ca^ j^ in immune cells using flow 
cytometry (FACScan)
2.37.1 -  Trypan blue exclusion
A trypan blue exclusion was carried out to determine the approximate number of 
viable cells before and after agonist and antagonist addition. Trypan blue was 
diluted 1/10 in PBS from stock solution (SIGMA). 10 pi trypan blue was added to 
10 pi cells. Viable cells were counted using a haemocytometer.
2.37.2 -  Addition of agonists and GABA, musbimol or glycine to cells
For each experiment carried out on the FACS, 1 ml of the loaded cell suspension 
was added to a clear FACS tube (BD Trucount™ absolute counting tube, BD 
Biosciences). Recordings were taken at 50,000 events per sample on the FLl 
channel (as this channel is best suited for the filter sets used for FLUO-3AM) and 
forward and side scatter were used to selectively gate the cell population. For 
kinetic analysis of [Ca^^i changes, events were continuously acquired with 
CellQuest Pro software (BD Biosciences) and the mean fluorescence of events 
acquired at 1 -  2 s intervals was calculated. Excitation was from an argon laser at 
506 nm, while emission at 526 nm was measured on a linear scale. 
Autofluorescence of non-loaded cells was used to set lower gating levels and 
voltage and gain settings were then adjusted in order to obtain a baseline 
fluorescence using unstimulated cells loaded with FLUO-3 AM.
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1 mM GAB A, 1 mM glycine or 100 pM muscimol, was added to a tube of 1 ml cell 
suspension, and incubated for 5s -  5 min. Agonists (1 nM fMLP, 1 mg/ml LPS) 
was then added to the cell suspension, and the fluorescence reading taken 
immediately. As a positive control, 1 pM ionomycin was added to the cell 
suspension in order to induce maximal Ca^  ^ release. Responses to agonists and 
antagonists were measured as arbitrary fluorescence units and were calculated by 
taking the median cellular fluorescence value.
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Chapter 3
Detection of GABAa and glycine 
receptor subunit mRNAs in 
immune cells.
3 -  RT- PCR detection of GABAa and glycine receptor 
subunits
Functional nicotinic ACh receptors have been reported to be present on mammalian 
immune cells (Fujii et a l, 1999; Kawashima and Fujii, 2000; Wang et a l, 2002) 
where they have been shown to modulate cell response to inflammation. A few 
reports have also suggested the presence of a few GABAa and glycine receptor 
subunit mRNAs in mouse (Bergeret et a l, 1998) and rat (Froh et al, 2002) primary 
immune cells (see section 1.6). However, to date the presence of functional inhibitory 
ligand-gated ion channels in human immune cells has not been clearly shown. The 
initial aim of this project was to determine if receptor subunit mRNAs could be 
detected in Jurkat J6 cells and human PBMC by using qualitative reverse transcriptase 
polymerase chain reactions (RT-PCR).
Primers were designed to regions corresponding to the intracellular loops between 
transmembrane domains M3 and M4, as this is the least conserved region between 
subunits, thereby increasing primer specificity. Also, a variation of the standard RT- 
PCR, termed ‘nested’ RT-PCRs were carried out in order to screen for each subunit. 
This was because it was assumed that any GABAa and glycine receptor subunits 
present would be expressed at low levels in immune cells. Although standard RT- 
PCR is a sensitive technique, its sensitivity can be further increased by performing 
nested RT-PCR. This involves taking an aliquot of the product from the primary RT- 
PCR, and using it as a template for a secondary round of PCR amplification. To avoid 
fiirther amplification of primer-dimer artifacts or nonspecific products generated in 
the primary PCR, a different set of primers were used in the second PCR reaction. 
These nested primers were internal to the primers used in the primary PCR (therefore 
termed ‘internal primers’), yielding a shorter PCR product.
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3 .2 - Results
Poly RNA isolated from whole brain (CLONTECH), was used as a positive 
control to test the specificity of the PCR conditions. The ratio of absorption (260:280 
nm) of all RNA preparations was in the range 1.8 -  2.0, indicating that protein 
contamination had not occurred.
3.2.1 -  Amplification of GABAa and glycine receptor subunit cDNAs
The PCR reaction performed on cDNA synthesised from the mRNA using specific 
up- and downstream primers gave amplification products of appropriate base pair 
lengths for each subunit analysed (Table 11 and 12). All experiments were repeated 
at least three times, using separate cDNA preparations each time in order to ensure 
that the results were consistent. Also, all RT-PCR products were confirmed by 
sequencing (see section 2.25). Figures 11 and 12 show representative ethidium 
bromide stained agarose gel electrophoresis of GABAa and glycine receptor subunit 
RT-PCR products.
The primers for the GABAa and glycine receptor subunits were designed according to 
published sequences and were optimised with regards to a standardised melting 
temperature (55 -  60° C) and primer dimer formation. Control experiments, where a 
PCR reaction was performed on RNA without including the reverse transcription step, 
did not produce any bands, thus confirming that total RNA was free from genomic 
DNA. A no template PCR was also performed as a negative control, to ensure that all 
components of the PCR reaction were free from contamination.
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Table 11: GABAa re cep to r su b u n it cDNAs am plified  from : B = hum an  brain  cDNA; J  =
Ju rk a t ceil cDNA; P = hum an  PBMC cDNA. '+' in d ica te s  th e  p re se n c e  o f th e  m o st 
in ten se ly  s ta in e d  PCR b an d s , ‘±’ in d ica te s  th e  p re s e n c e  o f fa in t b a n d s  an d  in d ica tes  








Present in : (Using 
external primers)
B J  P
Present in : (Using 
internal primers)
B J P
a l 241/95 55/55 + + + + + +
a2 207/90 55/55 + - - + -
o3 247/116 55/56 + + + + +  +
a4 487/254 56/53 + + + + + +
o5 216/134 53/57 + - - + -
a6 269/150 52/54 + ± - +
pi 321/112 53/57 + + - + +
P2 314/169 55/55 + + - + + +
P3 319/110 53/54 + + ± + + +
Ô 252/128 57/56 + - 4- + +
E 315/139 55/55 + + + + + +
Y2 244/137 56/56 + + - + + ±
y3 300/182 52/54 + - - + -
0 667/471 57/57 ± ± - ± ±
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Figure 11: R epresentative ethidium  brom ide s ta in ed  ag a ro se  gel e lec tro p h o resis  of
th e  RT-PCR p ro d u c ts  ob tained  using GABAa recep to r su b u n it specific external and 
internal prim ers. F igures 11 A(i) t o l l  N(i) show  PCR p ro d u c ts  ob tained  from  external 
prim ers. F igures 11 A(ii) t o l l  N(ii) show  PCR p ro d u c ts  ob tained  from internal prim ers.
1 2  3 4
Fig 11 A: (i) GABAa a l .  Lane 1; PBMC;
Lane 2: Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
(ii) G A B A a  a l .  Lane 1: 100 bp ladder;
Lane 2: PBMC; Lane 3: Jurkat; Lane 4:Brain
1 2  3 4
Fig 11 B: (i) GABAa a2. Lane 1:100 bp ladder 
Lane 2: Brain ; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) GABAa a2.. Lane 1: PBMC; Lane 2: 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
Fig 11 C: (i) GABAa a3. Lane 1:1000 bp ladder 
Lane 2: Brain ; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) GABAa a3.. Lane 1: PBMC; Lane 2: 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
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1 2  3 4
Fig 11 D: (i) GABAa a4. Lane 1:1000 bp ladder 
Lane 2: Brain ; Lane 3: Jurkat; Lane 4: PBMC
1 2 3 4
(ii) GABAa o4. Lane 1: 1000 bp ladder;
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
Fig 11 E: (i) GABAa o5. Lane 1; PBMC
Lane 2: Jurkat ; Lane 3: Brain ;Lane 4: 100 bp ladder
1 2  3 4
(ii) GABAa o5. Lane 1: PBMC; Lane 2; 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
Fig 11 F: (i) GABAa a6. Lane 1:100 bp ladder 
Lane 2: Brain ; Lane 3: PBMC; Lane 4: Jurkat
1 2  3 4
(ii) GABAa a6. Lane 1; 100 bp ladder;
Lane 2: Brain; Lane 3; Jurkat; Lane 4: PBMC
1 2  3 4
Fig 11 G: (i) GABAa pL Lane 1: PBMC
Lane 2: Brain ; Lane 3: Jurkat; Lane 4:100 bp ladder
1 2 3 4
(ii) G A B A a  pL Lane 1: 100 bp ladder;
Lane 2: Brain; Lane 3: PBMC; Lane 4: Jurkat
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1 2  3 4
Fig 11 H: (i) G A B A a  p2. Lane 1:1000 bp ladder 
Brain ; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) G A B A a  p2. Lane 1: PBMC; Lane 2: 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
Lane 2:
1 2  3 4
Fig 1 1 1: (i) G A B A a  P3. Lane 1:1000 bp ladder 
2: Brain ; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) G A B A a  P3. Lane 1: PBMC; Lane 2: Lane 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
Fig 11 J: (i) GABAa S.. Lane 1:1000 bp ladder 
Lane 2: Brain ; Lane 3: PBMC; Lane 4: Jurkat
1 2  3 4
(ii) G A B A a  8. Lane 1: 100 bp ladder;
Lane 2: Jurkat; Lane 3: Brain; Lane 4: PBMC
1 2  3 4
Fig 11 K: (i) GABAa e. Lane 1: Jurkat
Lane 2: PBMC ; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
(ii) GABAa G. Lane 1: 100 bp ladder; Lane 
2:Brain; Lane 3: Jurkat; Lane 4: PBMC
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1 2  3 4
Fig II L: (I) GABAa j 2. Lane 1: PBMC 
2: Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
1 2  3 4
(ii) GABAa y2. Lane 1: PBMC; Lane 2: Lane 
Jurkat; Lane 3; Brain; Lane 4:100 bp ladder
1 2 3 4
Fig 11 M: (i) GABAa y3. Lane 1:1000 bp ladder 
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) GABAa y3. Lane 1; 100 bp ladder; Lane 
2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
Fig 11 N; (i) GABAa 0 .  Lane 1 : Brain
Lane 2: PBMC; Lane 3: Jurkat; Lane 4:100 bp ladder
1 2  3 4
(ii) GABAa 0. Lane 1: PBMC; Lane 2: 
Jurkat; Lane 3: Brain; Lane 4:100 bp ladder
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Profiles of GABAa receptor subunit expression in human brain, Jurkat cells and 
human PBMC cDNAs are shown in Figure 11. As can be seen from Table 11 and 
Figure 11, all the GABAa receptor subunits tested were expressed in the brain. 
Differences in levels of expression of the same subunit were also noticeable in 
different mRNAs. For example, strong bands (at 319 bp) corresponding to the 
GABAa P3 subunit amplified by external primers were present in brain and Jurkat 
cDNAs, while only a faint band was detected in PBMC (Figure 11 Ii and lii).
The GABAa receptor a l  subunit was detected in brain, Jurkat and PBMC cDNA 
although the signal in the latter was weak in comparison to brain and Jurkat 
expression. However, it was detected by using both external and internal primers at 
the expected sizes of 241 and 95 bp respectively (Figures 11 Ai and Aii). While the
a2  and a5  subunits were only detected in brain cDNA (Figures 11 B and 11 E),
strong signals were detected for the a3 subunit cDNA in brain, PBMC and Jurkat 
cDNAs using both external and internal primers at 247 and 116 bp respectively 
(Figures 11 Ci and Cii). The GABAa receptor a4  subunit was also detected in brain, 
Jurkat and PBMC using both external and internal primers at 487 and 254 bp 
respectively, although interestingly, the product signal was weaker in the nested PCR
reaction (Figure 11 Dii). The a6  and pi subunits were only detected in brain and 
Jurkat cDNAs (Figures 11 F and IIG), and the P2 subunit was only detected in 
PBMC using internal primers. However, strong signals were detected in brain and 
Jurkat cDNAs using both external and internal primers (Figures 11 H). The P3 
subunit was detected at low levels in PBMC using internal primers (Figure 11 Ii), 
while a strong signal corresponding to the subunit was obtained using external 
primers (Figure 11 lii). Bands (252 and 128 bp) corresponding to the 5 subunit were 
detected in human brain and PBMC cDNAs, but was absent in Jurkat cDNA (Figure 
IIJ), while strong signals for the 8 subunit (315 and 139 bp) were detected in all 
three cDNA samples (Figure IIK). The 73 subunit cDNA was detected only in
human brain (Figure IIM), and strong signals for the 72 subunit was detected in 
human brain and Jurkat cDNAs, and a weak signal was detected in human PBMC 
(Figure 11L). Faint signals corresponding to the GABAa 0 subunit was detected in
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human brain and PBMC, but not in Jurkat cells at 667 and 471 bp (Figure 11 Ni and 
Nii).
Profiles of glycine receptor subunit expression in human brain, Jurkat cells and 
human PBMC cDNAs are summarised in Table 12 and shown in Figure 12.
Table 12: Glycine receptor subun it cDNAs amplified from: B = hum an 
brain cDNA; J  = Ju rka t cDNA; P = PBMC cDNA. * indicates sam ple w as 
amplified using Touchdown PCR (see below for conditions). ‘+ ’ 
indicates the p resence  of the m ost intensely stained  PCR bands, ‘±’ 



















a l 235/100 56*/60
a2 217/119 55/56 + -  - + -  -
a3 207/128 53/55 + -  - + -  -
p 284/158 55/55 T T + +
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Figure 12: Representative ethidium bromide stained agarose gel
electrophoresis of the RT-PCR products obtained using glycine receptor 
subunit specific external and internal primers. Figures 12 A(i) to 12 D(i) show 
PCR products obtained from external primers. Figures 12 A(ii) to 12 D(ii) show 
PCR products obtained from internal primers.
1 2  3 4
Fig 12 A: (i) Glycine a l .  Lane I: 100 bp ladder 
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) Glycine a l .  Lane 1: 100 bp ladder; Lane 
2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
Fig 12 B: (i) Glycine a2. Lane 1: 100 bp ladder 
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2 3 4
(ii) Glycine a2. Lane 1: 100 bp ladder; Lane 
2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
Fig 12 C: (i) Glycine a3. Lane 1: 100 bp ladder 
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
(ii) Glycine a3. Lane 1: 100 bp ladder; Lane 
2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2  3 4
Fig 12 D: (i) Glycine p. Lane 1: 100 bp ladder 
Lane 2: Brain; Lane 3: Jurkat; Lane 4: PBMC
1 2 3 4
(ii) Glycine p. Lane 1: 100 bp ladder; Lane 
2: PBMC; Lane 3: Brain; Lane 4: Jurkat
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The glycine receptor a l ,  a2 and a3 subunits were only detected in human brain
cDNA (Figures 12A -  12C). For the expression of glycine a l  subunit in brain, a 
specialised form of RT-PCR, termed ‘touchdown PCR’ was used. Touchdown PCR 
is a method for increasing specificity of PCR reactions by using a cycling program 
where the annealing temperature is gradually reduced by 1 -  2 °C every second 
cycle. The initial annealing temperature is usually set several degrees above the 
estimated Tm of the primers. Annealing temperature is then gradually decreased 
until it reaches the calculated annealing temperature of the primers or some degrees 
below. Amplification is then continued using this annealing temperature. The idea 
is that any differences in Tm between correct and incorrect annealing gives 
approximately a 2-fold difference in product amount per cycle (4-fold °C).
In order to amplify the glycine a l  subunit, touchdown PCR was performed using 
the external primers. The reaction was performed at 56, 54, 52, 50, and 48° C for 1 
min and 46° C for 2 min, for 35 cycles. The PCR product was then used as a 
template for a standard PCR reaction (at 55° C) using the internal primers. The 
expected 100 bp product derived from internal primers was observed from brain 
cDNA only (Figures 12 Ai and Aii). A no template control was performed in 
parallel, and did not give rise to any bands, thereby ruling out the possibility of
contamination. Touchdown PCR was also attempted to detect the a  subunits in 
Jurkat and PBMC cDNA, but the subunits could not be detected. However, 
standard RT-PCR produced bands corresponding to the glycine p subunit in brain 
and Jurkat cell cDNAs using external and internal primers. The PCR products 
were of the expected sizes at 284 and 158 bp (Figure 12D).
3.3 -  Quantitative RT- PCR
The data obtained through RT-PCR indicated that several ligand-gated chloride 
channel subunit mRNAs were present in human immune cells. However, in order
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to gain a better idea of the possible biological significance of this, quantitative 
measurements needed to be performed. Although RT-PCR is mainly used for 
qualitative studies, several modifications of this method have been developed that 
allow quantitative analysis. One such method is real-time RT-PCR which is a 
system based on the detection and quantitation of a fluorescent reporter, usually 
F AM (6-carboxyfluorescein) or SYBR Green. For the purposes of this project 
TaqMan RT-PCR was used for the quantitative detection of GABAa and glycine 
receptor subunit mRNAs. The fluorescent probes in this system use the fluorogenic 
5’ exonuclease activity of Taq DNA polymerase to measure the amount of target 
sequences in cDNA samples. The TaqMan probes used in this study contained the 
reporter fluorescent dye F AM on the 5’ base, and the energy-adsorbing quenching 
dye Methyl Red on the 3’ base. Methyl Red was used as it is superior to other 
available quenchers, in that it has no fluorescent emission of its own that can be 
detected by the sequence detector (ABI PRISM 7700 Sequence Detector System).
TaqMan primer and probe design is crucial to the success of the PCR reaction. The 
required parameters for well-designed primers and probes includes having a Tm for 
the probe that is at least 10°C higher than the primers, G-C content in probe to be in 
the 30 -  80% range, primers to be designed as close as possible to the probe without 
overlapping and the primer Tm being set between 58°C and 60°C. All primers and 
probes were designed using Primer Express Version 1.0 (Applied Biosystems), 
which was also used to select the position of the primer within the subunit 
sequence. Unlike qualitative RT-PCR, primers and probes were not exclusively 
designed to sequences within the M3 -  M4 loop.
When irradiated, the excited fluorescent dye transfers energy to the nearby 
quenching dye molecule rather than fluorescing. TaqMan probes were designed to 
anneal to an internal region of the PCR product. When the polymerase replicates a 
template on which a TaqMan probe is bound, its 5’ exonuclease activity cleaves the 
probe (Heid et.al 1996). This ends the activity of the quencher and the reporter 
dye starts to emit fluorescence which increases in each cycle proportional to the rate 
of probe cleavage. Accumulation of PCR products is therefore detected by 
monitoring the increase in fluorescence of the reporter dye (Wang and Brown,
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1999). Because the cleavage occurs only if the probe hybridises to the target, the 
fluorescence detected originates from specific amplification. Also, the monitoring 
of the whole reaction rather than just the end product permits the quantitation to be 
based on the early, linear part of the reaction. This permits a threshold cycle (Ct) to 
be determined at which fluorescence above background is first detected. Ct values 
correspond to the cycle number at which the fluorescence due to enrichment of the 
PCR product reaches significant levels above the background fluorescence 
(threshold).
TaqMan RT-PCR is a very sensitive method of detecting the presence of the 
original RNA, but it cannot be quantified without some standard against which to 
measure the final number of amplified strands. Normalisation is necessary to 
correct for possible variations in the template input amount among the samples, and 
methods commonly used include normalisation to p-actin mRNA, to 
glyceraldehyde 3-phosphate dehydrogenase mRNA, to 18S rRNA, and to the total 
RNA concentration. For the purposes of this project 18S rRNA was used as a 
housekeeping gene. A standard curve of ribosomal 18S rRNA was obtained for 
each sample and the Ct value for the 18S rRNA was subtracted from the Ct value of 
the target gene in order to normalise the data. The cycle number at which 
amplification of the product starts, corresponds to the levels at which its mRNA is 
present in the sample, i.e. the amplification of product at an early cycle indicates the 
presence of high levels of target mRNA. Therefore, in a 40-cycle PCR reaction, 
any amplification of products occurring after a Ct number of 35 were ignored.
Due to the high specificity and sensitivity of TaqMan RT-PCR, it was used to 
determine the presence of a number of GABAa and glycine receptor subunits in a 
variety of human tissues and immune cells including monocytes, CD4+, CD8+, 
irradiated B-cells, PBMC and neutrophils. Receptor subunit mRNAs displaying the 
most intensely stained PCR products fi*om human PBMC using standard RT-PCR 
were screened for. These included the a l ,  a3 , (32 and ^3 GABAa receptor 
subunits as well as the ô and 8 subunits. Also, RT-PCR results showed that only
the glycine p subunit mRNA was detected in Jurkat cells, and none of the subunits 
were present in PBMC. However, due to reports that functional glycine receptors 
may be present in rat neutrophils (Wheeler et a l, 2000), we used the TaqMan
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method to see if the glycine receptor subunits could be detected in a number of 
immune cells.
The 96-well plates used for the experiments were all prepared at AstraZeneca 
(R&D Chamwood, Loughborough). These contained an array of human tissues and 
immune cell cDNAs. RNA from whole human brain, heart, lung, liver, trachea and 
placenta were supplied as total RNA from Clontech or Invitrogen. All the immune 
cells used were isolated by flow cytometry (e.g. immature and mature dendritic 
cells and monocytes), immunomagnetic separation with dynabeads (e.g. CD4+ T 
cells, CD8+ T cells and B cells) or by using density gradient solutions (neutrophils 
and T-helper cells) at AstraZeneca (Loughborough). Total RNA was prepared 
using TRIzol and glycogen (GIBCO BRL) and then reverse-transcribed into cDNA 
with random hexamer primers and Superscript II (GIBCO BRL). The cDNA was 
then loaded onto the 96-well plates, where each sample was added to two separate 
wells.
3.3.1 -  Detection of GABAa receptor subunits
As expected, the highest amount of amplification of all GABAa receptor subunits 
was from whole brain (positive control), while amplification from other human 
tissues and immune cells was variable. The ai subunit cDNA was detected in small 
amounts from monocytes, CD8+ and irradiated B-cells and in slightly higher 
amounts in CD4+ cells. The subunit was detected at the highest amounts in
PBMCs (Figure 13). This was consistent with the amplification patterns of each 
sample. Figure 14 shows the amplification plot of the a i  subunit cDNA from (A) 
human brain and in (B) human PBMC, CD4+, CD8+ and irradiated B-cells. The 
PCR reaction was allowed to run for 40 cycles, and as can be seen in Figure 14A,
the (%i subunit cDNA started to amplify from the brain cDNA at a Ct value of 19. 
In PBMC, amplification occurred at a Ct of 22, while CD4+, CD8+, irradiated B 
cells and monocytes show amplification of the product at Ct values of 27, 28, 30
73
and 30 respectively (Figure 14B). This indicates that the GABAa receptor a l 
subunit is present at higher levels in PBMC cDNA in comparison to the other 
immune cells tested.
The GABAa receptor a3  subunit cDNA was expressed at low levels in CD4+ and 
iiTadiated B cells, although it was not detected in human PBMC or neutrophils. 
The GABAa receptor (32 subunit cDNA was amplified in variable amounts fi*om a 
number of tissues (Figure 15), especially lung and liver tissue. It was also detected 
in small amounts in monocytes, CD4+, CD8+, PBMC and neutrophils, although at
these low levels, the presence of fimctional (32 subunit polypeptides is somewhat 
questionable. Irradiated B cells showed the highest levels of detection compared to 
all the other immune cells tested. Low levels of the a l  and ^2 subunits were also 
detected in a mixed population of lymphocytes stimulated with the 
proinflammatory cytokine, tumor necrosis factor-a (TNF-a) for 6 hours. In 
contrast, the (33 subunit cDNA was expressed at negligible levels in non-neuronal 
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Figure 13: D istribution of GABAa recep to r a l  su b u n it cDNA in hum an tis su e s . 
TaqMan Ct values w ere converted  to  arbitrary units, followed by 18S rRNA 
norm alisation to  correc t for RNA quantity  and integrity. Data are m ean ± S.E. for 
dup licate  reverse  transcrip tion  reactions from each  mRNA pool. The black s ta rs  
indicate sam p les  of in terest.
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Figure 14: Amplification plot of the GABAa a l subunit from (A) human brain cDNA (red and lime plots) 
and (B) from A -  human PBMC (red and lime ); B -  CD4+ cells (sky blue and ); C -  CD8+ cells (navy
blue and pink); 0 -  Irradiated B-cells (dark blue and green); E -  Monocytes (red and lime) and F -  (sky 
blue and ) a no template control. Ct represents the cycle threshold, i.e. the PCR cycle number at
which fluorescence is detected above an arbitrary baseline. All samples were loaded onto the plates as 
duplicates the plots of which represented as pairs of colours.
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Figure 15: Distribution of GABAa p2 receptor subunit cDNA in human 
tissues. Data are expressed as arbitrary units normalised to 18 S RNA to 
correct for RNA quantity and integrity, and are mean ± S.E. for duplicate 
reverse transcription reactions from each mRNA pool. The black stars 
indicate samples of interest.
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Table 13 shows a comparison of mean Ct values of the various GABAa receptor 
subunits amplified from a variety o f human immune cells. The widest distribution 
o f ‘significant’ (i.e. where amplification has occurred at a Ct number lower than 35) 
levels o f subunit cDNA was observed for the GABAa (Xl and (32 subunits. The
GABAa receptor Ô and 8 subunit mRNAs had also been screened for. However, no 
significant amplification o f the subunit cDNAs were observed in any of the immune 
cells. This was probably due to poor primer and probe design, as amplification
levels of both the ô and 8 subunit in the brain cDNA was also low.
Table 13: Comparison of mean TaqMan Ct values of GABAa receptor
subunit amplification from human brain and immune cells (n=2). Results are 




TaqM an  
Result (Ct) 
from a l
TaqM an  
Result (Ct) 
from o3
TaqM an  
Result (Ct) 
from p2
TaqM an  
Result (Ct) 
from p3
W hole Brain 20 21 18 22
M onocyte 29 36 34 38
CD4+ 27 28 30 36
CD8+ 28 35 33 37
Irradiated B 
cell
31 31 25 39
Neutrophil 38 39 34 40
TNF6h 29 36 32 39
PBMC (own 
sam ple)
23 38 32 40
Neutrophil 
(own sam ple)
40 39 39 40
78
3.3.2 -  Detection of glycine receptor subunits
For the initial TaqMan studies, the possible presence of glycine receptor subunits 
was screened for in the same human tissues and immune cells as above. Overall, 
compared to the GABAa receptor subunit cDNAs, the amount of glycine receptor 
subunit cDNAs showed a wider level of detected at the highest levels in human 
brain.
Of all the glycine receptor subunits, the a l  subunit showed the widest level of 
distribution in human immune cells (Figure 16, Table 14). The subunit was 
detected in CD4+ and mature dendritic cells at higher levels compared to 
monocytes, CD8+, irradiated B cells and immature dendritic cells (Figure 16). Low
levels of the subunit were also detected in TNF-a stimulated lymphocytes (6 
hours), and T-helper clone cells (ThO, Thl and Th2). Highest levels of detection 
were present in TNF-a stimulated lymphocytes (24 hours) and PBMC cDNA. 
Figure 17A shows the amplification of the subunit in brain cDNA at cycle number 
17 and in PBMC and neutrophil cDNA at a Ct of 24 and 26 respectively (Figure 
17B).
The glycine a2 subunit mRNA also showed a wide level of distribution in the 
immune cells. Amplification occurred at high levels in CD4+ and PBMC cDNAs. 
Slightly lower levels were also detected in TNF-a stimulated lymphocytes (24 
hours) and neutrophils (own sample), while low levels were detected in cDNAs 
from immature and mature dendritic cells, CD8+ cells, irradiated B cells, and in 
neutrophils (Astrazeneca). T helper clone cells (stimulated Th2 clone) and
monocytes also showed low levels of amplification of the a2  subunit (Table 14).
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Figure 16: Distribution of glycine a l  receptor subunit cDNA in human tissues. Data 
are expressed as arbitrary units normalised to 18S RNA. Black stars are placed 
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(B) A m plification plot for glycine a l  subunit from hum an neutrophil cD N A
Am plification -  g lyc ino  a lICO
1 0 - 1
<
10-2
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 56 38 40
Cycle
Figure 17: Amplification plot of the glycine a l receptor subunit from (A) human brain and (B) human 
neutrophil cDNA. Samples were loaded onto the plates in duplicates (red and lime plots). Amplification 
of the product starts at cycle 14 in human brain. This takes place at a much later cycle numt>er (cycle 25) 
in human neutrophils. Ct represents the cycle threshold, i.e. the PCR cycle number at which fluorescence 
is detected above an arbitrary baseline.
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Compared to the glycine a l  and a2 subunits, the a3 subunit cDNA showed a 
slightly lower level of distribution in immune cells. It was detected in cDNAs from 
CD4+ cells and monocytes, but not from neutrophils or human PBMC (Table 14).
Other immune cells expressing the a3 subunit mRNA included CD8+, irradiated B 
cells and the T helper clone cells (stimulated Th2 clone). Highest levels of the 
glycine (3 subunit were detected in cDNA from lymphocytes stimulated with TNF- 
a  for 24 hours. High levels were also observed in cDNA from lymphocytes
stimulated with TNF-a for 6 hours, and also in tissues taken from fibroblasts of 
patients with rheumatoid arthritis (RA). In comparison, slightly lower levels of the 
subunit were detected in cDNAs from tissues taken from the synovium of RA 
patients, PBMC and neutrophils (own sample). Figure 19 shows the amplification 
plots of cDNAs from neutrophils (Figure 19A), PBMC and brain (Figure 19B), 
which have Ct values of 23,27 and 20 respectively.
Interestingly, the glycine a l ,  a2 and P subunits showed very different levels of 
detection in the two neutrophil samples. While in my own neutrophil cDNA 
sample it was observed at levels comparable to TNF-a stimulated lymphocyte
cDNA (24 hours), in the cDNA sample prepared at AstraZeneca levels of the a l  
subunit was barely detectable. Neutrophil isolation and cDNA synthesis from both 
samples had been prepared by using the same methods. The main variation was in 
the way the total RNA had been extracted, where I had used the method described 
in section 2.13, which being phenol and chloroform free, differs from the TRIzol 
and glycogen method. However, the TRIzol method is well established and is 
known to extract good quality RNA. A second difference in protocol was that I 
prepared total RNA from isolated neutrophils on the same day as the whole blood 
was collected (see section 2.6). This was to ensure minimal degradation of RNA. 
However, neutrophils isolated from whole blood at AstraZeneca was sometimes
frozen at -  80 °C, and RNA was extracted at a later date. If the glycine a l ,  a2
and p subunits are present at low levels in human neutrophils, then it could 
become degraded upon freezing and thawing the cells prior to total RNA extraction.
82








Figure 18: Distribution of glycine (3 receptor subunit cDNA in human tissues. Data 
are expressed as arbitrary units normalised to 18S RNA. Black stars are placed 
under samples of interest.
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(A) Amplification plot of glycine (3 subunit from human neutrophils cDNA
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(B) Amplification plot of glycine P subunit from human brain and human PBMC cDNA
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Figure 19: Amplification plot of the glycine p subunit from (A) human neutrophils (red and lime plots) and 
(B) human brain (sky blue and ) and human PBMC (red and lime) cDNAs. In human neutrophil
cDNA, the product starts to amplify around cycle 22, while in human brain cDNA, amplification of product 
starts around cycle 19. In human PBMC cDNA amplification starts around cycle 25. Ct represents the 
cycle threshold, i.e. the PCR cycle number at which fluorescence is detected above an arbitrary baseline. 
All samples were loaded onto the plates as duplicates which are represented by pairs of colours.
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Table 14: Comparison of mean TaqMan Ct values of glycine receptor subunit 
amplification from human brain and immune cells. Results are presented as 
arbitrary Ct values. Ct values lower than 35 are highlighted in blue.
Sam ple (source  
o f  RNA)
T aqM an  
R esult (Ct) 
from a l
TaqM an  
R esult (Ct) 
from a2
TaqM an  
R esult (Ct) 
from o3
TaqM an  
R esult (Ct) 
from p
W hole Brain 18 21 19 19
Im m ature DC 34 34 38 39
M ature DC 29 33 37 39
M onocyte 35 35 27 38
CD4+ 30 29 29 35
CD8+ 33 34 33 37
Irradiated B 
cell
34 32 31 38
Neutrophil 35 34 40 40
TNF6h 32 34 35 27
TNF 24h 26 30 31 23
ThO clone 34 35 36 39
Th1 clone 33 35 35 39
Th2 clone 
resting
35 37 35 40
Th2 clone 
stim ulated
34 34 33 40
PBMC (own 
sam ple)
24 26 36 26
Neutrophil 
(own sam ple)
26 30 40 28
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These results showed that a number of the GABAa and glycine subunits are 
detected in a number of human immune cells, and in cells involved in inflammatory 
reactions (e.g. TNF-a stimulated cells, and synovium and fibroblasts from RA 
patients). Table 15 shows a comparison of the detection levels of some of these 
subunits in the immune cells of interest. The main difference lies in the 
neutrophils, where in contrast to the glycine receptor subunits, the GABAa receptor 
subunits are clearly absent.
Table 15: A co m p ariso n  o f th e  levels  o f d e tec tio n  o f GABAa an d  g lycine recep to r 
su b u n it cDNAs in a  ra n g e  o f h u m an  im m une ce lls . Levels a re  ind icated  w ith th e  ‘+’ 
sym bol (with +++ ind icating  h igh levels  o f  e x p re ss io n , ++ a s  m edium  levels, + a s  low 
levels an d  - a s  n o  ex p re ss io n .
Receptor
subunit




GABAa oti + + + + + - + + +
GABAa 0C3 - + - + - -
GABAa P2 - + + + + - +
GABAa P3 - - - - - -
Glycine a l - + - - + + + +
Glycine a2 + + + + + + + + +
Glycine a3 + +  + + + - -
Glycine P - - - - +  + + +
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3.4 -  Discussion
Analysis of GABAa and glycine receptor subunit expression in cDNA from total 
human brain (positive control), human PBMC and Jurkat J6 cells, was performed 
by reverse transcription polymerase chain reaction. The PCR analysis showed that 
receptor subunit cDNAs corresponding to a number of GABAa and glycine 
receptor subunits could clearly be detected (Figures 11 and 12). In the nervous 
system, the most common functional receptor subunit stoichiometry is alp2y2 , 
a2piy2 (Backus et al, 1993) and a2p2yl (Chang et.al, 1996; Tretter et.al, 1997) 
and 75% of functional GABAa receptors contain a benzodiazepine binding site. 
However, the ô and 8 subunits are reported to be able to replace the y subunit to 
form a functional GABAa receptor (Sieghart et a l , 2000).
3.4.1 -  P resence of GABAA-receptor a  and P subun its  in immune cells
The RT-PCR results showed that the mRNAs for a l, a3 and a4 and all three p 
subunits of the GABAa receptor were detected in Jurkat and PBMC cDNAs. The 
a6 subunit was only detected in Jurkat cells, while the aS subunit was absent from 
both PBMC and Jurkat cells. Both a and p subunits are crucial for the formation of 
functional GABAa receptors, so these results show that due to the wide distribution 
of these two subunit types, and the presence of the Ô and 8 subunits in PBMC, it is 
reasonable to suggest there may be functional GABAa receptors present on immune 
cells.
Real-time quantitative RT-PCR showed that the cell and tissue distribution profile 
of the GABAa receptor subunits was variable (Table 13 and 15). Apart from the
detection of the a l  subunit in human PBMC (Figure 13, Figure 14B), none of the 
four subunits tested seemed to be expressed at high levels in PBMC or neutrophils. 
The a3  and p2 subunits were expressed at lower levels in CD4+ and irradiated B 
cells, while the p3 subunit was not detected in any of the immune cells. This was
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in contrast to the results obtained from qualitative RT-PCR, where the a3  and (33 
subunit mRNAs were clearly present in PBMC. This was probably due to the 
differences in primer sequences used for the two methods. Taking the qualitative 
RT-PCR results into account, this probably suggests poor primer design.
3.4.2 -  Absence of GABAa receptor y  subunits in immune cells
RT-PCRs carried out on cDNA’s from human brain, PBMC and Jurkat cells, using 
the yl external and internal primers produced large smears on the gel. In an 
attempt to produce clear and specific bands corresponding to the subunit, the Mg^  ^
concentration in the buffer was varied, the primer pairs were redesigned, and 
touchdown RT-PCR was performed. However, despite changing all or some of 
these factors, the large smears were never removed. It could therefore not be
determined from these studies if the yl subunit is present in immune cells.
One interesting point to note is that the y3 subunit cDNA was not detected in Jurkat
and PBMC (Figure 11 M). Also, only a faint band corresponding to the y2 subunit 
was detected in PBMC using nested PCR (Figure 11 Lii). A similar result was 
found by Bergeret et al, (1998), where neither the yl or y2 were expressed in PS 15 
(mouse mast cell) and H9 T cell-lines. To date, some of the best established 
GABAa receptor pharmacology is the sensitivity of the receptor to 
benzodiazepines. However, in order to confer benzodiazepine sensitivity, the a  and 
P subunits must be co-expressed with a y subunit (MacDonald & Olsen, 1994; 
Rabow et al 1995), as the binding pocket for benzodiazepines is located in a 
subunit cleft between the y and a  subunits (Sigel, 2002). Therefore, the absence of
the y subunits suggests that any GABAa receptors in immunocompetent cells will 
not display benzodiazepine potentiation, unlike the GABAa receptors in the CNS.
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3.4.3 -  Detection of glycine subunits in immune cells
While the glycine receptor p subunit was detected in Jurkat cell cDNA, none of the 
a subunits were detected in either Jurkat or human PBMC. In order to have a 
functional glycine receptor, the presence of at least three a subunits is essential. 
Therefore, this absence of glycine receptor a subunit mRNAs made it unlikely that 
any functional glycine receptors are present in immune cells. To date, there is no 
published data to suggest otherwise, although in a study conducted by Froh et al 
(2002), the a l, o2 and p subunit mRNAs were detected in rat peritoneal 
neutrophils.
Real-time quantitative RT-PCR showed that the expression levels of glycine 
subunit cDNAs (Tables 14 and 15) were higher than those of the GABAa receptor 
subunit cDNAs. This was in contrast to the results obtained in the qualitative RT- 
PCR, where none of the glycine receptor subunits were detected in PBMC cDNA, 
The reason for this disparity is unclear. It is possible that the subunits are present at 
low levels in the immune cells, which could not be detected by the less sensitive 
qualitative PCR.
Detection levels of the glycine a l ,  a2  and p receptor subunits were higher in 
PBMC and neutrophils in comparison to most other immune cells (Figure 16, 
Figure 17B, Table 14). In contrast, the Œg subunit was barely detectable in PBMC 
and neutrophils, while high levels of the subunit was expressed in CD4+ cells and 
monocytes. The glycine P subunit had lower distribution levels in immune cells
compared to the a  subunit cDNAs, although moderately high levels were expressed 
in neutrophils and PBMC, indicating the presence of these subunits on these cell 
types. One main difference between GABAa receptor subunit and glycine receptor 
subunit expression was the high levels of glycine receptor subunit expression in
mixed lymphocyte populations stimulated for 24 h with TNF-a, which showed
amplification at a Ct of 26. TNF-a is a proinflammatory cytokine produced 
primarily by monocytes and macrophages, and it is known to activate T cells to lead
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to increased inflammatory responses. Also the T-helper clone subsets (ThO, Thl 
and Th2) cells showed expression of the glycine a l  subunit (Table 14). Thl and 
Th2 cells in particular, are closely involved with cell mediated inflammatory 
reactions (through cytokine release and modulation of allergic responses), and 
studies have shown that the cluster differentiation antigen CD30, which is a 
member of the TNF receptor family, is expressed on Th2 cells (Roitt et a l, 1998).
The presence of the glycine a l  subunit on these cells would therefore suggest that 
functional glycine receptors may be involved in the modulation of T cell responses.
Overall, the qualitative and quantitative RT-PCR data have shown that the mRNAs 
to a number of GABAa and glycine receptor subunits are clearly present in human 
immune cells. However, the data from the two RT-PCR techniques are not always
in agreement, in particular with respect to the GABAa a3  subunit and glycine a l  -  
3 subunit expressions. In general, real-time RT-PCR is regarded as being a more 
sensitive and reliable technique compared with standard RT-PCR. The low levels 
of GABAa a3  and p3 subunits detected by the TaqMan method does not 
necessarily negate the standard RT-PCR results. As the levels of expression of both 
subunits in all the immune cells (apart from a3  in CD4+ cells) was very low, it 
could be argued that the particular primer/probe combination used for these 
subunits were not ideal.
It can be assumed that any functional GABAa receptors on human PBMCs will 
contain a land  p2 subunits and may also include 5 and s subunits. On CD4+ and
irradiated B-cells, functional receptors may contain a l ,  a3 and p2 subunits. The 
quantitative data also suggests that any functional glycine receptors present on 
human PBMC and neutrophils will contain a l ,  a2 and p subunits. It also suggests 
that any functional glycine receptors present on CD4+ and irradiated B cells will 
comprise of homomeric or heteromeric a2 and a3 receptor subunits. Therefore, 
these findings showed that our original hypothesis that functional GABAa and 
glycine receptors are present on human immune cells may be correct. The next step
90
in the project was to determine if the proteins corresponding to these receptor 
subunit mRNAs could be detected in human immune ceils.
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Chapter 4
Expression of the GABAa receptor 
a1 subunit polypeptide in human
immune cells
4 -  Expression of GABAa receptor a1 subunit
To date, there is no published data showing the presence of GABAa receptor and 
glycine receptor subunit proteins in human immune cells. Our results from both 
qualitative and quantitative RT-PCR clearly showed that a number of GABAa and 
glycine receptor subunit mRNAs was detected in Jurkat cells, human PBMC and
CD4+ cells. We attempted to detect the GABAa receptor a l ,  a3, P2 and ^3 
subunits, and glycine a l  subunit in immune cells using immunoblotting and
immunofluorescence. The glycine a l  antibody (abeam) used in these experiments 
was a polyclonal antibody raised against a KLH-conjugated synthetic peptide from 
the amino terminus of the human a l  glycine receptor subunit, which also cross- 
reacts vyith the human glycine receptor a2 subunit. Affinity-purified goat polyclonal 
GABAa receptor a3, p2 and p3 antibodies, raised against peptides mapping the
GABAa receptor a3 (N-19), P2 (C-20) and p3 (C-20) of human origin (Santa Cruz 
Biotechnology) were used in the experiments. Unfortunately, these commercial 
antibodies resulted in high levels of non-specific staining.
An affinity-purified anti-GABAA receptor a i  subunit antibody (a gift from Prof. Anne 
Stephenson, London School of Pharmacy) was used in all protein expression studies. 
This antibody was raised in Dutch-belted rabbits against a KLH-conjugated synthetic 
peptide (sequence PEKPKKVKDPLIKKNNT), and is directed against the
intracellular loop (324-341) of the bovine GABAa receptor a l  subunit sequence 
(Duggan and Stephenson, 1990). The GABAa receptor has been well studied in the 
mammalian brain. Studies conducted in bovine cerebral cortex by Stephenson et al 
(1988) showed that the GABAa receptor consists of alpha (53 kDa) and beta (57 kDa)
subunits, and more refined protein chemistry revealed the existence of multiple a-
and p-subunit isoforms (Buchstaller et a l, 1991a; Buchstaller et a l, 1991b). Studies 
using anti-peptide antibodies have shown that, at the protein level, the most abundant 
of the GABAa receptor a-subunit isoforms is the a l  subunit (Stephenson, 1988). In
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whole rat brain it is reported to constitute 40% or more of detergent-solubilized 
receptor binding, and has a size of 50-51 kDa (McKeman et a l, 1991).
4.1 -  Results
4.1.1 -  GABAa a1  receptor subunit expression in rat brain 
and immune cells
Western blots were carried out on membrane preparations from rat brain, Jurkat J6 
cells, HL-60 cells, HEK-293 cells and human PBMC. Whole cell lysate preparations 
from human T-cells, human neutrophils and BaF3 cells were also used in 
immunoblotting studies. BaF3 cells, a mouse pro-B cell line, were a gift from Dr. 
Melanie Wellham, Department of Pharmacy and Pharmacology, University of Bath 
and HEK-293 cells were a gift from Katherine Ralphs, Department of Biology and 
Biochemistry, University of Bath.
Proteins in the membrane preparations and cell lysate samples were separated by 
SDS-PAGE and then transferred onto nitrocellulose membranes, where they were
exposed to the anti- GABAa Otl antibody. A band of the expected size at ~ 50 kDa 
was present in the preparations from rat brain, Jurkat J6 cells, HL-60 cells, BaF3 cells, 
isolated human PBMC and isolated human T-cells (Figure 20). The band was absent 
from isolated human neutrophils and HEK-293 cells (negative control). A strong 
band at ~ 37 kDa was also present in rat brain, Jurkat, HL-60, neutrophils, T-cells and 
BaF3 cells, but was absent in PBMC and HEK cells.
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Figure 20: W estern  blot using affinity-purified anti-GABAA a i recep to r su b u n it 
an tibod ies. Lane 1: BIORAD precision  broad range protein s tan d a rd  (~ 15 pg). Lane 2: 
M em brane p reparation  from  to tal rat brain (15 pg) (positive control). Lane 3: 
M em brane p reparation  from  Ju rk a t J6  cells (30 pg). Lane 4: M em brane p reparation  
from  HL-60 cells (30 pg). Lane 5: M em brane p reparation  from  hum an PBMC (30 pg). 
Lane 6: M em brane p reparation  from  HEK-293 cells (30 pg) (negative control). Lane 7: 
Cell lysate ob tained  from  isolated  hum an neu troph ils (40 pg). Lane 8: Cell lysate from  
isolated  hum an T ce lls (40 pg). Lane 9: Cell lysate  from  BaF3 cells (40 pg).
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4.1.2 -  Immunofluorescent detection of the GABAa receptor 
a l  subunit
In order to confirm and extend the Western blot results, immimofluorescence 
experiments were carried out on Jurkat J6 cells, HL-60 cells and human neutrophils
PBMC and HEK-293 cells. All cells were treated with anti-GABAA Otl antibody, the 
specific binding of which was detected by FITC-conjugated or Texas Red-conjugated 
anti-rabbit immunoglobulins. HEK-293 cells were used as a negative control, and as 
expected only background staining was observed (Figure 28B). These cells were also 
treated with anti-beta tubulin antibody which was detected by FITC-conjugated anti­
rat immunoglobulins. These cells showed the characteristic p-tubulin staining pattern 
(Figure 28A).
Leukocytes express distinct assortments of molecules on their cell surfaces, many of 
which reflect either different stages of their lineage-specific differentiation or 
different states of activation or inactivation. One such assortment is the cluster of 
differentiation (CD) antigens which are present on the leukocyte cell surface. 
Therefore, a number of anti-CD antigen (CD3, CD4, CD14 and CD19) antibodies
were also used alongside the GABAa Otl antibody to identify specific cell types in 
mixed populations such as PBMC.
CD3 is a complex of at least five membrane-bound polypeptides found in mature T- 
lymphocytes. The polypeptides are non-covalently associated with one another and 
with the T cell receptor (Koning et a l, 1990; Roitt et a l, 1998; Kastrup et a l 2002). 
The anti-CD3 antibody was used to treat isolated PBMCs and Jurkat J6 cells. Anti- 
CD4 antibody was also used to treat isolated PBMCs. CD4 is a 55-kD glycoprotein 
originally defined as differentiation antigens on T cells, but also found on other cells 
including monocytes and macrophages. On T cells they define the helper/inducer 
subset (Roitt et a l, 1998). CD 14 are glycolipid-anchored membrane glycoproteins 
expressed on cells of the myelomonocyte lineage including monocytes, macrophages, 
and some granulocytes. They function as receptors for the complex of
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lipopolysaccharide (LPS) and LPS-binding protein (Calvano et a l, 2003; Latz et a l, 
2003). Flow cytometry and confocal microscopy studies have shown that intracellular 
CD 14 is present in approximately 90% of human neutrophils (Rodeberg et a l, 1997). 
Anti-CD 14 antibodies were used to treat HL-60 cells as well as isolated PBMCs and 
neutrophils. Firrally, CD\9 are differentiation antigens expressed onB  ceBs and B 
cell precursors. They are involved in regulation of B cell proliferation (de Rie et a l, 
1989; Callard et a l, 1992). The anti-CD19 antibody was used to treat B cells within 
the PBMC preparation.
In order to detect the GABAa receptor a l  subunit, cells were treated with the
polyclonal anti- a l  antibody, which was detected with FITC-conjugated anti-rabbit 
immunoglobulins, and anti-CD antibodies were detected with Texas Red-conjugated 
anti-mouse immunoglobulins. In Jurkat cells GABAa a l  immunoreactivity was 
present in the cytoplasm and to a lesser extent associated with the plasma membrane 
(Figure 21 A). As Jurkat cells are a T-cell line, these were also labelled with 
monoclonal antibodies to CD3. Immunofluorescence was detected mainly on or near 
the plasma membrane and some diffuse staining in the cytoplasm was also present 
(Figure 2IB). The merged image (Figure 21C) shows a level of co-localisation 
around the plasma membrane of the cells. Negative controls were carried out for each 
experiment, where cells were labelled with secondary antibody only (Figure 21 D).
HL-60 cells (Figure 22) showed a similar result with respect to GABAa a l  
immunoreactivity (Figure 22 A). As these cells are a promyelocytic cell line, they 
were also labelled with the monocyte marker, CD-14. Anti-CD 14 was localised to the 
cytoplasm (Figure 22 B), and the merged image (Figure 22 C) showed a high level of 
co-localisation of the two antigens.
Isolated PBMCs were labelled with a number of different CD antigens, as the 
preparation contained a mixed population of cells (mainly T-cells, B-cells and 
monocytes). As in Jurkat cells, anti-CD3 fluorescence was developed mainly around 
the plasma membrane with some staining of the cytoplasm occurring as well (Figure 
23B). This pattern of staining was also observed with anti-CD4 antibodies (Figure 
24C). PBMCs treated with anti-CD 14 showed two different types of staining (Figure 
25B). While most of the cells in the preparation labelled by the antibody showed
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diffuse cytoplasmic immunofluorescence, about 10% of the cells showed strong 
staining around the plasma membrane. These cells also showed this type of
immunoreactivity for GABAa a l .  Anti-CD 19 also showed strong staining around 
the plasma membrane, while diffuse staining in the cytoplasm was absent (Figure 
26B). Figure 27A shows that the neutrophils used in this study, showed a similar
pattern of immunoreactivity for CD 14. However, the anti-GABAA a l  antibody 
showed non-specific staining in the cells (Figure 27B).
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Figure 21 : (A) Jurkat cells labelled with GABAa antl-a1 and FITC conjugated antl rabbit IgG. (B) Jurkat cells 
labelled with antl-CD3 and Texas Red conjugated anti-mouse secondary antibody. (C) Merged Image of 
panels A and B. (D) Negative control. Cells labelled with FITC conjugated antl-rabbit secondary antibody 
only. Calibration bar 10 pm.
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BD
Figure 22: (A) HL-60 cells labelled with GABAa antl-a1 and FITC conjugated 
antl-rabbit IgG. (B) HL-60 cells labelled with antl-CD14 and Texas Red 
conjugated anti-mouse secondary antibody. (0) Merged Image of panels A and 
B. (D) Negative control. Cells labelled with FITC conjugated antl-rabbit 
secondary antibody only. Calibration bar 10 pm.
1 0 0
DFigure 23: (A) Isolated human PBMCs labelled with GABAa anti-al and FITC 
conjugated anti-rabbit IgG. (B) PBMCs labelled with anti-CD3 and Texas Red 
conjugated anti-mouse IgG. (C) Merged image of panels A and B. (D) Cells 
viewed under transmitted light. Calibration bar 10 pm.
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DFigure 24: (A) Isolated human PBMCs labelled with GABAa antl-ai and FITC 
conjugated antl-rabbit IgG. (B) Negative control. Cells labelled with FITC 
conjugated antl-rabbit secondary antibody. (C) PBMC labelled with antl-CD4 
and Texas Red conjugated anti-mouse IgG. (D) Negative control. Cells labelled 
with Texas Red conjugated anti-mouse secondary antibody . Calibration bar
10 pim.
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Figure 25: (A) Isolated human PBMC labelled with GABAa antl-ai and FITC conjugated antl- 
rabbit IgG. (B) PBMC labelled with antl-CD14 and Texas Red conjugated anti-mouse IgG. (C) 
Cells In panels A and B viewed under transmitted light. (D) Negative control. Cells labelled with 
FITC conjugated antl-rabbit secondary antibody. (E) Cells In panel D viewed under transmitted 




Figure 26: (A) Isolated human PBMCs labelled with GABAa antl-ai and FITC 
conjugated antl-rabbit IgG (B) PBMCs labelled with antl-CD19 and Texas Red 
conjugated anti-mouse IgG. (C) Negative control. PBMCs labelled with FITC 
conjugated antl-rabbit secondary antibody. (D) Cells In panel C viewed under 





Figure 27: (A) Isolated human neutrophils labelled with GABAa antl-ai and Texas Red 
conjugated antl-rabbit IgG. (B) Neutrophils labelled with antl-CD14 and FITC conjugated anti­
mouse IgG (C) Cells In panels A and B viewed under transmitted light. (D) Negative control. 
Neutrophils labelled with FITC conjugated anti-mouse secondary antibody. (E) Neutrophils In 
panel D viewed under transmitted light. Calibration bar 10 pm.
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Figure 28: (A) HEK-293 cells labelled with anti-beta tubulin and FITC-
conjugated anti-rat IgG. (B) HEK-293 cells labelled with anti-GABAA a1 and 
Texas Red conjugated antl-rabbit IgG.
106
4.2 -  Discussion
Immunoblotting and immunofluorescence experiments showed that the GABAa 
receptor tti subunit protein is expressed at low levels in Jurkat cells, HL-60 cells 
and human PBMC, but are clearly absent from human neutrophils. The 
immunoblotting results showed that a band at ~ 50 kDa was observed in rat brain, 
Jurkat cells, HL-60 cells, human PBMC, human T-cells and BaF3 cells. This was
close to the expected molecular weight of GABAa Cti receptor subunit based on 
studies by Duggan & Stephenson (1989) and Aller et al (2003), where the subunit 
was detected at 48 kDa (in bovine brain) and 51-53 kDa (in chicken brain) 
respectively. A band at 37 kDa was also present in all of the cells apart from 
PBMC and HEK-293 cells.
CD3 antigens are present on the plasma membrane of 60-80% of T-cells. CD4 
antigens are present on the surface of helper T cells (CD4+ cells). Normal CD4+ 
cells make up 20-30% of lymphocytes. Immunofluorescence of both anti-CD3 and 
anti-CD4 was present around the plasma membrane which was as expected (Revy 
et a/., 2001). This confirms our results from the TaqMan studies which had shown
that the a l  subunit mRNA could be detected in CD4+ cells. The CD 14 antibody 
immunofluorescence was mainly present in the cytoplasmic (possibly azurophilic) 
granules in HL-60 cells and in most of the PBMCs. However, some cells in the 
PBMC preparation showed anti-CD 14 staining only around the plasma membrane. 
This distinct pattern was only observed in about 10% of the cells, which showed a
similar pattern of immunofluorescence for anti-GABAA CXi. This suggests that 
these cells may not be the more common T or B cells, which make up 90% of the 
PBMC preparation, but may be monocytes, which make up about 10-15% of the 
preparation. Also, CD 14 antigens are known to be present on the plasma 
membrane of ~ 95% of monocytes (Rodeberg et a l, 1997). It has also been found 
on B cells and T cells (Labeta et a l, 1991; Terstappen et a l 1990). Therefore, the 
cells showing diffuse cytoplasmic staining could be T and B cells. CD 14 antigens 
are found on the plasma membrane of 20 -  40% of human neutrophils (Ball et a l, 
1982; Jayaram & Hogg, 1989), and in azurophilic granules (primary lysosomes) of 
human neutrophils (Rodeberg et a l, 1997). The neutrophils in these experiments
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showed cytoplasmic staining, and the characteristic multi-lobed nucleus is very 
clear in a few cells, which also showed the most fluorescence.
The results, together with the qualitative and quantitative RT-PCR results clearly 
shows that the GABAa receptor a l  subunit can be detected at low levels in human 
PBMC at both the RNA and the protein level. Human PBMC, Jurkat, HL-60, T 
cells and BaF3 cells all show a l  subunit expression, while neutrophils do not. 
From these studies it can be suggested that any functional GABAA receptors 
present will contain the a l  subunit. Based on the RT-PCR results it had been 
suggested that GABAa receptor a l, a3 and P2 subunits may form functional 
GABAa receptors on peripheral blood mononuclear cells, and the glycine receptor 
a l, a2 and p subunits may form any functional glycine receptors present. 
Therefore, immunoblotting and immunofluoresecence studies had also been carried 
out using antibodies to the GABAa a3, P2 and P3 subunits, and also the glycine 
a l, a2 and P subunit. Unfortunately these antibodies were all from commercial 
sources and resulted in high levels of non-specific staining.
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Chapter 5
The effects of GABA and glycine 
on agonist induced [Ca *^]i 
release in mammalian immune
cells
5.1 -  Glycine induced inhibition of intracellular free Ca *^ in rat 
neutrophils -  published data.
Neutrophils are mobile phagocytic cells that are the central effector cells in human 
innate immune responses to microbial and inflammatory stimuli (see Section 1.2.2, 
Figure 3D). These cells are activated by several extracellular signals, including 
exposure to formylpeptides derived from bacterial proteins or disrupted cells and 
bacterial derived endotoxins such as lipopolysaccharides (Schiffman et a/., 1975; 
Forehand et a l, 1989; Troelstra et a l, 1999). The best studied member of the 
formylpeptide family is the chemotactic synthetic tripeptide, N-fbrmyl-methionine- 
leucine-phenylalanine (fMLP), and specific receptors to this peptide have been 
identified on neutrophil plasma membranes (Tennenberg et a l, 1988; de Nardin et a l, 
1991; Radel et a l, 1994). The human fMLP receptor is a seven-transmembrane- 
domain structure characteristic of the G-protein-coupled receptor superfamily (Boulay 
et a l, 1990), while LPS is recognized in mammals by a receptor complex composed 
of CD 14, and Toll-like receptor 4 (TLR4) (Latz et a l, 2003).
The plasma membrane of mammalian cells contains two classes of calcium channels, 
which are either receptor-operated channels or voltage-operated channels. The 
opening of voltage-operated channels is dependent on the membrane potential of the 
plasma membrane which is a function of distribution of ions in the basal state. When 
fMLP or LPS bind to receptors on the neutrophil plasma membrane they cause a rapid 
depolarisation of the membrane potential. Interaction of fMLP or LPS with the 
receptor results in activation of phospholipase C (PLC) and specific guanine 
nucleotide regulatory proteins (G proteins) (Koo et a l, 1983; Guthrie et a l, 1984; Lad 
et a l, 1984; Rosoff et a l, 1985; Smith et a l, 1985; Prpic et a l, 1987), thereby 
degrading membrane-associated phosphatidylinositol-4,5-bisphosphate (PIP2) 
(Berridge and Irvine, 1984; Prentki et a l, 1984). This leads to the generation of 
second messengers such as diacylglycerol (DAG) and the intracellular messenger 
inositol 1,4,5-tris-phosphate (IP3). Interaction of IP3 with its receptor-operated Ca^  ^
channel in the ER results in rapid Ca^  ^release from ER stores. This leads to depletion 
of ER Ca^  ^stores and subsequently activates Ca^  ^influx across the plasma membrane
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(Bokoch and Gilman, 1984; Cockcroft et a l, 1984; Smith et a l, 1985, Forehand et al, 
1989; Krause et al, 1993; Wheeler et al, 2000; Chen and Jan, 2001).
Recent studies by Wheeler et al (2000) have demonstrated that glycine blunts the 
response of rat neutrophils to LPS and to fMLP. They studied the effect of glycine on 
increases in [Ca^^i elicited either by fMLP or LPS in individual rat neutrophils using 
the calcium indicator Fura 2AM and fluorescence microscopy. Activated rat 
neutrophils were isolated, plated onto glass coverslips and then loaded with 5 mM 
Fura 2AM. The cells were incubated with ImM glycine for 3 min before being 
exposed to either 1 pM fMLP or 100 pg/ml LPS. The results showed that the agonist 
effect was almost totally inhibited by 1 mM glycine.
They also measured radiolabeled chloride movement in the adherent neutrophils. The 
cells were incubated with ^^ Cl" and the tests showed that ImM glycine caused a dose- 
dependent increase in ^^ Cl" influx. 1 pM strychnine, a glycine-gated chloride channel 
inhibitor (Ito and Cherubini, 1991; Ikejima et a l, 1997) strongly inhibited this glycine 
stimulated ^^ Cl" influx. Also, as activation of a glycine-gated chloride channel in the 
neutrophil would be dependent on the presence of extracellular chloride they 
substituted chloride with the impermeable anion, gluconate. This led to an almost 
complete prevention of the inhibitory effect of glycine on agonist-induced increases in 
[Ca^ J^i. Also, Froh and Wheeler (2002) showed the expression of the glycine receptor
Cl2, a 4  and P subunit mRNAs in rat neutrophils. The glycine a l  subunit was 
detected in rat peritoneal neutrophils by immunoprécipitation and western blotting. 
Based on these studies, it was suggested that rat neutrophils contain a functional 
glycine-gated chloride channel similar to the glycine receptors expressed in neuronal 
tissues.
In order to explain these findings, Wheeler et al. (2000) hypothesised that when 
glycine binds to its receptor on the plasma membrane of the neutrophils, it activates 
its Cl- gated channel leading to an influx of Cl- that hyperpolarizes the cell 
membrane. These changes in membrane potential across both the cell and the 
endoplasmic reticulum membranes, decreases the open probability of the voltage- 
gated Ca2+ channels, therefore blocking movement of Ca2+ across the plasma
111
membrane and Cl' induced Ca^^ release from intracellular stores after addition of 
fMLP or LPS (Langosch et al ,  1990). In addition, influx of chloride could also 
inactivate the IP3-gated Ca^^ channel on the ER. and therefore blunt the release of 
[Ca^^Jj, resulting in an inhibition of neutrophil function. This proposed hypothesis is 









F ig u re  29: P ro p o s e d  m e c h a n is m  fo r in h ib itio n  o f a g o n is t- in d u c e d  in c r e a s e s  in 
[Ca^^i by  g ly c in e . A d a p te d  from  W h e e le r  et al., 2000. W h en  g ly c in e  e n te r s  th e  
ce ll, it le a d s  to  an  influx  o f Cl'. T h is  c a u s e s  th e  p la s m a  m e m b ra n e  to  
h y p e rp o la r iz e , m ak in g  o p e n in g  o f v o lta g e -g a te d  c a lc iu m  c h a n n e ls  o n  th e  ce ll 
s u r f a c e  m o re  d ifficult, th e re b y  d im in ish in g  r e s p o n s e s  to  fMLP a n d  LPS (a s  w ell 
a s  a  v a r ie ty  o f  o th e r  a g o n is ts )  th a t  d e p o la r is e  th e  ce ll m e m b ra n e .
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5.2 -  Inhibition of [Ca *^]i release from human neutrophils
Based on these results and the data obtained from real-time quantitative RT-PCR 
showing the detection of glycine a l ,  a 2 and p subunits in human neutrophils (see 
Section 3.2.3; Figures 16 and 17), it was hypothesised that functional chloride- 
gated glycine receptors will also be present on human neutrophils. If functional 
inhibitory ligand gated ion channel receptors, such as glycine and GABAa 
receptors, are present on these cells, they could play an important role in 
modulating inflammatory cell responses.
Intracellular calcium in neutrophils was measured fluorometrically using the 
calcium indicator FLUO-3AM (Tef Labs), and the fluorescence imaging plate 
reader (FLIPR). The FLIPR is a high throughput screening system that is an 
extremely sensitive fluorescence detector (and therefore, ideally suited for kinetic, 
cell-based assays, including measuring changes in intracellular calcium levels). The 
FLIPR integrates a powerful argon laser to excite the fluorescent dye, a CCD 
(charged couple device) imaging camera and a programmable 96-well pipettor to 
perform fluorometric analyses on all 96 wells of a microplate simultaneously. This 
system generates real-time kinetic data by stimulating and reading all 96 wells in 1- 
second intervals.
FLU0-3AM is a visible light-excitable Ca^  ^ indicator that is essentially 
nonfluorescent unless bound to Ca^ .^ It combines high fluorescence intensity upon 
Ca^  ^ binding with an absorption and emission spectrum very similar to that of 
fluorescein (Minta et a l, 1989). Its fluorescence intensity increases about 100-fold 
after binding of Ca^  ^with 506 nm as the optimum excitation wavelength and 526 
nm as the maximum emission wavelength. As the levels of [Ca^ j^i increase, the 
fluorescence of FLUO-3AM increases, leading to increased light output. The 
acetoxymethyl ester form of the dye was used as it is membrane permeate. After 
the FLUO-3AM is taken up by the cell, the ester is hydrolysed by an esterase in the 
cytoplasm to release the free acid form of the dye (FLUO-3), which then binds to 
Ca^ .^ FLUO-3 has a low affinity for Ca^  ^ (Kd = 400 nM), and does not display
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significant wavelength shifts after Ca^  ^ binding (Minta et.al, 1989). This low 
affinity for Ca^  ^makes it theoretically a more attractive compound for measuring 
transient [Ca^^i peaks than the UV light-excitable ratiometric Ca^  ^indicator, Fura 2 
(Kd = 224 nM), which was the probe used by Wheeler et al. (2000).
5.3 -  Results
5.3.1 -  Concentration-response curves for fMLP and LPS on 
increases In [Ca^ *];
The effect of various concentrations of fMLP (Figure 31) and LPS (Figure 32) on 
[Ca^ j^i in human neutrophils were carried out to determine the EC50 values for each 
agonist. Effects of fMLP were maximal at 1 nM with an EC50 of 0,42 pM. LPS 
increased [Ca^^i maximally at 1 mg/ml and had an EC50 of 35 pg/ml. In fact, the 
response curve for LPS indicates that the maximal response may be obtained at 
concentrations higher than 1 mg/ml.
Data were fit to the following equation:
y=VmaxfX"/E” + X ‘)J
Where, y = the pharmacologic response of the drug concentration X 
Vmax = is the maximum possible pharmacologic response 
K = is the concentration of the drug at which y = V2 Vmax 
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Figure 30: Concentration response curves for fMLP. Log of concentrations are plotted
against background fluorescence. Maximal effects of fMLP were observed at 1 nM.
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Figure 31 : Concentration response curves for LPS. Log of concentrations are plotted 
against background fluorescence . The maximum dose of LPS used was 1 mg/ml, and this 
showed the strongest response. However, the maximal effects obtained from LPS appears to 
require a higher concentration.
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5.3.2 -  Effects of fMLP on [Ca^ ]^j levels in human neutrophils
in human neutrophils was measured fluorometrically using the fluorescent 
Ca^^  indicator FLUO-3AM. Treatment with 1 nM fMLP caused a transient 
increase in [Ca^ ]^i. Intracellular calcium was assessed by monitoring changes in 
fluorescence intensity of FLUO-3 AM at excitation wavelengths of 506 nm with 
emission at 540 nm in the cells. This was measured every 2 seconds over 2 
minutes. Figure 32 depicts a representative response to fMLP (InM), where the 
agonist can be seen to cause a rapid increase in [Ca  ^ ]i within seconds followed by 
a gradual decrease, which reached a plateau and never returned to basal levels, 
confirming work by others (Wheeler et al, 2000). This effect was inhibited by 
exposing the neutrophils to 100 pM sulfasalamide, which is known to inhibit the 
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Figure 32: The effect of InM fMLP on [Ca^ j^; in human neutrophils. 100 pM sulfasalamide, a 
known fMLP blocker, is seen to inhibit this effect
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5.3.3 -  Effects of GABA and glycine on agonist-induced
increases in [Ca^ ]^j in human neutrophils
Human neutrophils were incubated in assay buffer containing GABA or glycine (3 
mM -  30 pM) for 5 min before and during the addition of the agonist. Figure 33 
shows the effect of glycine and GABA at ImM respectively on fMLP-induced 
increases in [Ca^ ]^j in neutrophils. Neither compound had any significant effect on 
the levels of [Ca^^]j.
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Figure 33 : The effect of 1 mM GABA (A) and ImM glycine (B) on fMLP-induced increases 
in [Ca^ l^i in human neutrophils. Data shown are representative of experiments repeated 3-4 
times.
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1 mg/ml LPS was also used to induce release of intracellular calcium from 
neutrophils. Once again, this effect was not affected by exposure of cells to varying 
concentrations of GABA and glycine. Figure 34 shows the effect observed upon 
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Figure 34: The effect of 1 mM GABA (A) and ImM glycine (B) on LPS-induced increases in 
[Ca^ l^i in human neutrophils. Data shown are representative of experiments repeated 3-4 
times.
118
5.4 -  Flow cytometry analysis of [Ca *^]i release
As the results obtained clearly showed that neither GABA nor glycine induced any 
changes in fMLP and LPS stimulated [Ca^^i release in human neutrophils, we 
carried out the experiment on rat neutrophils in an attempt to repeat the 
observations by Wheeler et al (2000). However, due to a lack of similar 
equipment, and lower obtainable quantities of rat blood, we used flow cytometry 
via a FACS Vantage (Becton Dickinson) to measure any changes in fluorescence as 
a result of [Ca^ ]^i release.
Flow cytometry involves the use of a laser beam projected through a continuous 
single-file liquid stream that contains cells, or other particles. The momentary 
pulse of fluorescence emitted as the cell crosses the beam is measured by a set of 
three photomultipliers at a 90° angle from the beam. The cytometer measures a 
number of factors based on scattering and emission of the light and uses this data to 
differentiate between and count the types of cells in the mixture. Some of the main 
aspects measured include low angle forward scatter intensity, which is 
approximately proportional to cell diameter; side (90 degree) scatter intensity, 
approximately proportional to the quantity of granular structures within the cell; 
and fluorescence intensities at several wavelengths. A histogram or dot plot of each 
cell can be created from these data.
5.4.1 -  FACS analysis of release from rat and human 
Immune cells
When the Ca^  ^indicator FLUO-3AM penetrates the cells, a major spectral change 
can be measured at an excitation wavelength of 506 nm. In the following 
experiments, cells were loaded with 5 pm FLU0-3AM for 90 min at room 
temperature (see section 2.37.3) and then immediately run on the flow cytometer to 
obtain fluorescence histograms at an emission wavelength of 526 nm. Rat and 
human PBMCs were studied in addition to rat neutrophils, as RT-PCR data had
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shown that a number of GABAa and glycine receptor subunits could be detected in 
human PBMCs (see table 11 and 13), and protein expression studies had shown the 
GABAa a l  subunit to be present at low levels in other immune cells (Figures 21 -  
27).
Measurements of fluorescence after addition of the agonist were taken immediately, 
as the fMLP and LPS response occurs witliin seconds of addition. Data were 
collected on the FLl channel (or ‘green fluorescence’ channel) as histograms of a 
log scale of intensity of fluorescence (X axis) against arbitrary fluorescence counts 
(Y axis) (see 2.37.3). Changes in fluorescence were estimated by a shift of the peak 
to the right (indicating increase of fluorescence) or left (decrease in fluorescence) 
along the X axis. In order to determine baseline fluorescence, readings were taken 
from unstimulated cells in assay buffer only (Figure 35, blue closed histogram). 
Neutrophils stimulated with 1 nM fMLP (Figure 35, green open histogram) showed 
a shift of the histogram to the right, indicating an increase in fluorescence due to 
[Ca^^i release. In order to confirm that increased fluorescence observed was due to 
the action of fMLP, 100 pM sulfasalamide was added to the cells 1 min before 
addition of InM fMLP. As expected, this led to inhibition of fMLP induced [Ca^^i 
release, thereby significantly reducing the fluorescence histogram shift to the right 
(Figure 35, pink open histogram).
Cells were incubated with GABA or glycine from 5s to 5 min. These different 
incubation times had no effects on fluorescence measured, and on cell viability 
(determined by trypan blue exclusion. See section 2.37.2). Figure 36 shows 
fluorescence from cells incubated with glycine for 5 min (Figure 36 A) before 
addition of 1 mg/ml LPS. The histograms are clearly superimposable, indicating 
that glycine had no effect on LPS stimulated [Ca^^i release. A similar result was 
observed upon application of GABA to rat neutrophils. However, when GABA 
was added to rat PBMCs for 5 s (Figure 36 B) before addition of fMLP, a small 
decrease in fluorescence could be observed. As PBMCs are a mixed population of 
cells (T cell, B cells and monocytes), it is likely that only one or two of the cell 
populations were responding to GABA treatment. From the histogram, it appears 
to be the population of cells giving rise to the smaller peak that were responding to
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GABA treatment, while the larger peak remained unchanged with respect to 
fluorescence intensity. No such effect was observed upon application of GABA to 
LPS stimulated cells, and upon application of glycine to rat PBMCs stimulated with 
fMLP and LPS. Table 16 summarises the results obtained from rat neutrophils and 
PBMC.
Buffer
InlM fM LP + 100 uM sulfasalamide  
InM fM LP
10^ 10' 
F luorescence Intensity (Log)
Figure 35: FL1 h istog ram s show ing ch a n g es  in flu o rescen ce  in rat neu troph ils. In 
o rder to  determ ine base line  fluo rescence , read in g s w ere taken from  unstim ulated  
cells in a s sa y  buffer only (blue c losed  h istogram ). N eutrophils stim ulated  with 1 nM 
fMLP (green open  h istogram ) show ed  a sh ift (of th e  histogram ) to  th e  right, 
indicating an increase  in flu o rescen ce  d u e  to  [Ca^*], re lease. W hen 100 gM 
su lfasalam ide, w as added  to  th e  cells (pink o p en  histogram ) flu o rescen ce  d u e  to  
addition of fMLP w as significantly reduced .
121
(A) p
I mg/ml LPS 










o o  .
C  O  J










Fig 36: FL1 histograms of rat neutrophils (A) and rat PBMCs (B). In (A) neutrophils stimulated with 1 
mg/ml LPS (blue closed histogram) caused an increase in fluorescence, which was not inhibited upon 
incubation of cells with 1 mM glycine (green open histogram). Similarly, PBMCs (B) stimulated with 1 nM 
fMLP (blue closed histogram) caused an increase in fluorescence. 1 mM GABA (green open histogram) 
leads to a small decrease of fMLP induced fluorescence.
1 2 2
Table 16: Average m edian values indicating ch an g es  in flu o rescen ce  in tensities
from rat neutrophils and PBMC.
R at ce ll ty p e A g o n is t T re a tm e n t In c u b a tio n
tim e
(s e c o n d s ) ,
w ith
a n ta g o n is t
M ed ian
(M ean, ±  SD ) 
(n=3)
Neutrophils nM tMLP 100 (± 11)
Neutrophils nM tMLP ImM GABA 98 (± 3 5 )
Neutrophils 1 nM tMLP ImM glycine 180 102 (±  63)
Neutrophils 1 nM fMLP 100 pM 
sulfasalamide
60 47 (± 19)
Neutrophils mg/ml LPS 99 (± 16)
Neutrophils 1 mg/ml LPS ImM GABA 92 (± 4 1 )
Neutrophils 1 mg/ml LPS ImM glycine 300 9 1 (± 17)
PBMCs 1 nM tMLP 103 (± 15)
PBMCs 1 nM tMLP ImM GABA 95 (± 24)
PBMCs 1 nM tMLP ImM glycine 120 97 (± 28 )
PBMCs nM fMLP 100 pM 
sulfasalamide
60 39 (± 14)
PBMCs mg/ml LPS 91 (± 19)
PBMCs mg/ml LPS ImM GABA 87 (± 48)
PBMCs 1 mg/ml LPS ImM glycine 300 86 (± 44)
In order to quantitate the fluorescence intensity, the median of the histograms were 
compared. The median refers to the middle of the population, i.e. the point at 
which there are 50% of the collected events on either side of the channel. It 
therefore gives a robust estimate of intensity characterising a population of cells. 
However, it must also be taken into account that PBMCs are a mixed population of 
cells, so median values can show variability between cell samples. From Table 16 
it can be seen that only median values obtained from cells incubated with 100 pM 
sulfasalamide showed a significant decrease in fMLP stimulated fluorescence 
(neutrophils: 47 ± 19, n=3; PBMCs: 39 ± 14, n=3). Changes in median values from 
cells exposed to 1 mM glycine over various incubation times showed no significant 
change, which was also observed with ImM GABA. However, rat PBMCs 
exposed to GABA over 5 seconds prior to addition of fMLP showed a small
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decrease in fluorescence (87 ± 48, n=3). Similar experiments in human PBMCs 
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Figure 37: Comparison of representative dot plots of rat neutrophils (A) rat PBMCs (B) and human 
PBMCs (C). Each dot represents a single cell. Its position indicates its forward scatter (FSC) intensity 
value (cell size) on the X axis and its side scatter (SSC) intensity value (cell granularity) on the Y axis. 
Data were collected on the FL1 channel on a log scale.
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The dot plots show unstimulated rat neutrophils (Figure 37A), rat PBMC (Figure 
37B) and human PBMC (Figure 37C), where each dot represents a single cell. In 
Figures 37B and 37C, 2 distinct populations of cells can be seen, as opposed to one 
main population in A. This was expected as the PBMC preparation contains T and 
B cells as well as monocytes. Even though both rat PBMCs and human PBMCs 
display two main cell populations, this is more distinct in human PBMCs. Also, 
side scatter is higher in rat PBMCs reflecting that these cells are more granular than 
human cells. This is in agreement with findings that PBMC fi*om animals such as 
rats, mice and rabbits tend to have a higher density than human PBMCs (Boyum et 
a l, 1991). Forward scatter for both rat and human PBMCs is very similar, 
indicating that the cells fi’om the two main populations are of similar size.
As expected, addition of 1 nM fMLP (121 ± 16, n =3) and 1 mg/ml LPS (84 ±17, 
n=3) to human PBMCs led to an increase in fluorescence (Figures 38A and 38B, 
blue closed histogram). Addition of 1 mM GABA to LPS stimulated cells splits the 
histogram into two distinct peaks (Figure 38B, green open histogram). The 
histogram also shifted slightly to the left indicating a decrease in fluorescence (76 ± 
30, n =3). Addition of 1 mM glycine to human PBMCs for 2 min before addition 
of fMLP showed no change in fluorescence (114 ± 35, n =3), (Figure 38 A, green 
open histogram). In contrast, when PBMCs were treated with 1 mM GABA for 5 s 
prior to addition of fMLP (67 ± 23, n =3), the histogram shifts to the left and splits 
into two peaks (Figure 39 A), once again indicating that cell populations within the 
PBMC fi*action differ in their response to GABA. This response was investigated 
further by gating the two main populations of cells (Figure 40). This showed that 
the population of cells corresponding to the larger peak responded to treatment with 
GABA by a reduction in fluorescence fi*om 10^  ^ to 10^  fluorescence units (log). 
However, the population of cells corresponding to the smaller peak showed no 
change in fluorescence. In order to determine if this GABA response was taking 
place via GABAa receptors, 100 pM muscimol, a GABAa receptor agonist was 
also added to the cells (Figure 39B, pink open histogram). Once again, the 
histogram spilts into two peaks and shifts to the left. However, in contrast to the 
GABA response, both peaks show a decrease in fluorescence intensity (55 ± 30, n 
=3). The GABAa receptor antagonist, bicuculline was also added to the cells at 30 
pM for 5 min prior to addition of GABA (Figure 39B green open histogram). This
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showed a reversal of the effects of GABA on fMLP stimulated cells, as the 
histogram showed no decrease in fluorescence (115 ± 20, n = 3), although a small 
spilt of the peak can be observed. Table 17 summarises the results obtained from 
human PBMCs.
I nM fM LP  
I mlM Glycine + I nlM fM LP
(A) Fluorescence Intensity (Log)
I mg/ml LPS 
Im M  GABA + I mg/ml LPS
(B) Fluorescence Intensity (Log)
Figure 38: FL1 histograms demonstrating changes in fluorescence in human PBMCs. In (A) cells
stimulated with 1 nM fMLP (blue closed histogram) caused an increase in fluorescence, which was not 
inhibited upon incubation of cells with 1 mM glycine (green open histogram). In (8) cells stimulated with 1 
mg/ml LPS (blue closed histogram) caused an increase in fluorescence. Addition of 1 mM GABA (green 
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Figure 39: FL1 histograms d em onstrating  c h a n g e s  in flu o rescen ce  in human PBMCs 
stimulated with 1 nM fMLP (blue closed histogram). In (A) cells were incubated with 1mM 
GABA before addition of fMLP (green open histogram). In (B) ce lls w ere ex p o sed  to  100 










Dot plot A 1 nM fMLP + 1 mM GABA





Dot Plot B 1 nM fMLP 1 nM fMLP + 1 mM GABA
Figure 40 : Gating of PBMCs in figure 39A. The gated dot plots correspond to figure 370.
Only cell population (R1) shown in dot plot A, respond to addition of 1 mM GABA by shifting 
to the lefL Cell population (R2), shown in dot plot B, remains unchanged.
Table 17: Average m edian values Indicating ch a n g es  in flu o rescen ce  in tensities for
hum an PBMCs.
A g o n is t T re a tm e n t In c u b a tio n
tim e
(s e c o n d s ) ,
w ith
a n ta g o n is t
M edian
(M ean, ±  SD) 
(n=3)
I nM tMLP - - 121 (± 16)
I nM tMLP ImM GABA 5 67 (± 23)
1 nM tMLP too |iM 
muscimol
120 55 (± 30)
1 nM tMLP ImM glycine 120 1 1 4 (±  35)
1 nM fMLP 100 pM 
baclofen
180 119 (± 2 1 )






1 nM tMLP 100 faM 
sulphasalamide
60 41 (± 18)
1 mg/ml LPS - - 84 (± 17)
1 mg/ml LPS ImM GABA 5 76 (± 30)
1 mg/ml LPS ImM glycine 120 78 (± 27)
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5 .5 - Discussion
Activation of rat and human immune cells with 1 nM fMLP and 1 mg/ml LPS 
clearly leads to a dose-dependent elevation of [Ca^^j. fMLP caused a rapid 
increase in [Ca^ ]^i within seconds followed by a gradual decrease, which reached a 
plateau and never returned to basal levels (Figure 32). This was similar to results 
found by others (Wheeler et a l, 2000; Jaconi et a l, 1988), where 1 pM fMLP was 
used to stimulate [Ca^^i release from rat neutrophils. This initial increase in 
calcium has been suggested to be from intracellular stores, whereas the sustained 
increase is the result of calcium influx from the extracellular space (Forehand et a l, 
1989; Krause et al, 1993; Wheeler et al, 2000; Chen and Jan, 2001). These effects 
induced by fMLP were blunted by the addition of 100 pM sulfasalamide, which is a 
known to be able to block fMLP binding to human neutrophils (Stenson et al, 
1984), (Figure 32 and 35). Although LPS also leads to an increase in [Ca^^i, 
relatively high concentrations were required to achieve this effect, and it is possible 
that the maximal response induced by LPS could lie at a higher concentration than 
1 mg/ml (Fig 31). This was also higher than the concentration used by Wheeler et 
al (2000) on rat neutrophils, where 100 pg/ml LPS was used to elicit [Ca^^j 
release.
The results from these experiments showed that unlike the effects observed by 
Wheeler et al (2000), neither glycine nor GABA were seen to inhibit the fMLP and 
LPS induced increases in [Ca^^i in human neutrophils (Figure 33 and Figure 34). 
This was somewhat surprising as in the rat neutrophils studied in that paper, glycine 
had almost completely blunted the effects induced by both agonists. The fact that 
the response was so different in these experiments could be due to a number of 
reasons. Firstly, it could be hypothesised that rat neutrophils express a high number 
of glycine-gated chloride channels, compared to human cells, which is why 
Wheeler et a l (2000), were able to obtain strong responses. Also, Wheeler et a l 
had carried out single cell measurements on adherent neutrophils, unlike the 
method used in this project where calcium release was measured from a population 
of neutrophils in suspension. Studies have shown that adherence of neutrophils 
interferes with the characteristics of both calcium and O '^ generation, probably by
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modifying the cytoskeleton structure (Dahinden et a l, 1983; Rebut-Bonneton et a l, 
1988; Tanigawa et a l, 1993). This could lead to changes in neutrophil response to 
stimuli, and could account for some of the differences observed in the results 
obtained in this experiment.
The neutrophils used by Wheeler et al had been isolated and cultured in a different 
way to the neutrophils we isolated from human blood (see section 2.6). Wheeler et 
al had administered 1% glycogen to act as an inflammatory agent to the cells. 
These neutrophils were therefore activated and migrated to the peritoneum where 
they were collected by lavage. Studies have shown that although this technique 
elicits a 95% pure population of neutrophils, the cells display a phenotype that is 
dramatically different compared to quiescent neutrophils, for example with regard 
to their internal cytoskeletal arrangement and surface expression of adhesion 
molecules and receptors (Becker et a l, 1990; al-Mokdad et a l, 1997; Roussel and 
Gingras, 1997; Poon et a l, 1999; Wagner and Roth, 2000; Cotter et a l, 2001). 
Therefore, this exposure of the neutrophils to glycogen and the migration of the 
cells into the peritoneum could alter the activity of the neutrophils in the assay. It 
could be argued that the differences between the effects of glycine on the quiescent 
neutrophils used in this project, and the activated neutrophils used in Wheeler’s 
study was due to the latter cells having already been engaged in an inflammatory 
response. Also, fMLP stimulation of neutrophils induces changes in the expression 
of surface receptors (Solomkin et a l, 1994; Videm and Strand, 2004), and it is 
possible that receptor expression in adherent neutrophils can be upregulated more 
readily than neutrophils in suspension (Balazovich et al, 1996).
An additional point to add is that the GABAa receptors in particular, are fast-acting 
ligand-gated ion channels, and in the brain receptor activation is followed within 
milliseconds. Therefore, the incubation times used in this experiment for both 
transmitters of 3 Os-5 min could have led to desensitisation of any functional 
GABAa or glycine receptors present on the cells. However, Wheeler et a l had 
incubated the rat neutrophils with 1 mM glycine for 3 min before the addition of 
fMLP and LPS. Even though we had used both higher and lower incubation times 
than this, our results showed that the same concentration of glycine had no effect on 
[Ca^^i release from human neutrophils.
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Having been unable to repeat Wheeler et al. ’s findings in human neutrophils, I then 
used rat neutrophils (in suspension) to determine if glycine or GABA had any 
inhibitory effects on [Ca^^j release (Figure 36A). However, these studies also 
clearly showed that treatment with GABA or glycine had no effect on the agonist 
induced [Ca^^i release. In contrast, rat PBMCs showed a small decrease in 
fluorescence upon application of GABA to 1 nM fMLP stimulated cells (95 ± 24, n 
=3; Figure 36B). This effect was also observed in human PBMCs although the shift 
of the histogram peak to the left was of a higher magnitude when cells were 
exposed to 1 mM GABA prior to stimulation with 1 nM fMLP (67 ± 23, n = 3), 
(but not to stimulation with 1 mg/ml LPS; 76 ± 30, n = 3; Figure 39A). This effect 
was also reversed upon application of 30 pM of the GABAa receptor antagonist, 
bicuculline (115 ± 20, n =3). Addition of 100 pM of the GABAa receptor agonist 
muscimol (100 pM) also led to a small decrease in fluorescence (55 ± 30, n =3; 
Figure 39B), which was not observed upon application of the GABAb receptor 
agonist baclofen (100 pM; 119 ± 21, n =3). These results showed that the effects 
of GABA on human and rat PBMC was taking place via GABAa receptors and not 
GABAb receptors.
Another observation in responses fi’om human PBMC was that the histogram split 
into two peaks upon application of GABA to fMLP stimulated cells, indicating that 
at least two different populations of cells were responding to GABA treatment in 
different ways (Figure 39A). Upon gating of each cell population (Figures 39A and 
40), it was seen that only the cell group lying closest to the Y axis were showing a 
decrease in fluorescence in response to addition of 1 mM GABA. Addition of 
muscimol to fMLP stimulated PBMCs also led to a splitting of the histogram into 
two peaks, although this was not as distinctive as the effect seen with GABA. 
However, in contrast to the GABA response, the whole histogram shifts to the left, 
showing that all the cells in the PBMC fi*action respond to application of muscimol. 
In the nervous system, muscimol is known to have a higher affinity for GABAa 
receptors than GABA (Baur and Sigel, 2003). Based on this, if functional GABAa 
receptors are present on immune cells, then muscimol may be able to bind to these 
receptors with a higher affinity which would explain why all the cells in the PBMC 
flection respond to muscimol addition.
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Bicuculline addition also caused the histogram to split into two peaks, although this 
efifect was even smaller than that of muscimol (Figure 39B). Cells in the PBMC 
fraction are clearly responding to G ABA in a different way to muscimol and 
bicuculline. One way to identify if these cells were T or B cells or monocytes, 
would be to label the PBMCs with fluorescent cell-type specific antibodies (e.g. 
anti-CD3, anti-CD 19 and anti-CD 14), and to then sort these cells according to the 
fluorescent dyes used. However, this could not be carried out as the responses to 
G ABA and muscimol were somewhat variable. The cause for this is not entirely 
known, but one possible reason may be because as mentioned above GABAa 
receptors in particular, are fast-acting ligand-gated ion channels. Therefore, the 
incubation times for the transmitter could have led to desensitisation of any 
functional GABAa receptors present on the cells. Based on these points it seems 
evident that using the FACS for these experiments is perhaps not the best option, as 
compounds have to be added and mixed manually before placing the tube 
containing cells into the machine. This leaves room for human error in terms of 
keeping to exact times, etc. From the experiments carried out in the FLIPR, it was 
clear that the fMLP and LPS response took place within seconds of addition. Any 
delay on my part in placing the cells into the FACS after addition of both 
compounds led to a significant decrease in fluorescence readings.
The results from real-time quantitative RT-PCR showed that human neutrophils and 
PBMCs contained low level expression of mRNAs for a l ,  a2  and P glycine 
receptor subunits. However, no glycine receptor subunits could be detected in 
human PBMCs via qualitative RT-PCR. This is possibly because the high 
sensitivity of real-time RT-PCR had been able to detect the low level expression of 
these receptor subunits. Protein expression studies had also been carried out on
human PBMCs and neutrophil using anti- a l ,  anti-a2 and anti-p glycine subunit 
antibodies. However, due to a high level of background staining, the presence of 
glycine receptor subunits on immune cells could not be shown. In the above 
experiments, addition of 1 mM glycine consistently had no significant effects on 
agonist induced [Ca^^i release from the human and rat neutrophils and PBMCs 
(Figures 36A and 38A).
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Overall these studies clearly show that the presence of functional glycine receptors 
on human and rat neutrophils is unlikely. This is in contrast to data published by 
Wheeler et a l (2000), where the presence of functional glycine receptors on rat 
neutrophils was strongly suggested. However, functional GABAa receptors on 
human PBMCs and possibly also on rat PBMCs, may be present. Data from RT- 
PCR and protein expression studies showed the expression of a number of GABAa 
receptor subunits, in particular, the GABAa a l  subunit. GAB A and muscimol also 
appear to modulate the immune cell response to inflammatory stimuli such as fMLP 
and LPS. Even though these effects were small, they were relatively consistent, 
although the magnitude of the response varied somewhat. This was probably 
because immune cells are subject to donor variation due to conditions such as cell 
activation as a result of a cold or an allergic reaction etc. Sometimes immune cells 
from the same donor showed variations in magnitude of response to addition of 
G ABA or muscimol. This was particularly true if the donor was stressed or was 
suffering from a cold. In these cases, even though cell response to fMLP and LPS 
was relatively consistent, GABA and muscimol seemed to have a slightly stronger 
effect on reducing [Ca^ j^i release. Although these were casual observations, it 
could be explained by the fact that a cold or infection will lead to upregulation and 
activation of immune cells, which may lead to stronger responses to external 
stimuli. Also, studies have shown that fMLP stimulation of immune cells at low 
concentrations, selectively triggers directional movement and sustained [Ca^^i 
oscillations whereas higher concentrations initiates secretory functions (e.g. 
production of superoxide anions) which is concomitant with [Ca^^i release (Jaconi 
et a l, 1988). These dose-dependent changes in cell function could explain the 
limited effect of GABA in these assays, due to the maximal stimulation being given 
to the cells. Further tests should be performed to determine if GABA has a more 
potent effect on cells stimulated with lower doses of fMLP.
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Conclusion
The qualitative and quantitative RT-PCRs and the immunoblotting and 
imunofluorescence experiments have all shown that the GABAa receptor a l  
subunit mRNA and protein are present in human peripheral blood mononuclear 
cells. The RT-PCR results showed the presence of GABAa 6 and 8 subunits 
mRNAs. Neither y2 or y3 subunit mRNAs were detected in human PBMCs, an 
observation which agrees with findings by Bergeret et a l (1998) who reported that 
RT-PCR studies on PS 15 mast cells and H9 T cells showed no signals 
corresponding to yl and y2 subunit mRNAs. These results suggest that GABAa 
receptors in immune cells would not exhibit benzodiazepine potentiation. The Ô 
and 8 subunits can replace y subunits to form benzodiazepine-insensitive functional 
GABAa receptors (Shivers et a l, 1989; Sommer et a l, 1990; Davies et a l, 1997; 
Moss and Smart, 2001), and these receptors differ in their pharmacological profiles 
to y containing receptors (Saxena and Macdonald, 1994; Mehta and Ticku, 1999; 
Sinkkonen et a l, 2000).
Studies of recombinant GABAa receptors report that the potency of inhibition by 
the external blocker, Zn^ ,^ is profoundly affected by the subunit composition of the 
receptor (Draguhn et a l, 1990; Smart et a l, 1991). GABAa receptors composed of 
aPy subunits show markedly lower sensitivity to Zn^  ^ compared to apô and aP8 
receptors (Draguhn et a l, 1990; Smart et a l, 1991; Saxena and Macdonald, 1994; 
Saxena and Macdonald, 1996; Whiting et a l, 1997; Krishek et a l, 1998). Also, 
cells expressing a ip i8  GABAa receptors show reduced sensitivity to the 
anaesthetic 2,6-diisopropylphenol (propofol) and the benzodiazepine flunitrazepam 
(Whiting et a l 1997; Davies et a l, 2001), compared to cells containing aipiy2s  
GABAa receptors. Additionally, a lp l8  receptors exhibit rapid desensitization 
kinetics, as compared with a lp l or aip iy2s GABAa receptors (Davies et a l, 
2001), and alp38 receptors show increased potency and efficacy of direct 
activation by the barbiturate pentobarbital, neurosteroids and the partial GABAa 
agonists piperidine-4-sulphonic acid and thio-4-PIOL, as compared to alp3y2  
GABAa receptors (Maksay et a l, 2003). These distinct pharmacological profiles
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could be used to carry out further studies to test for the presence of ô and 8 
containing functional GABAa receptor subunits in human immune cells.
FLIPR and FACS methods were used in this project to study changes in [Ca^ j^i 
release from human and rat neutrophils and PBMCs, and the results clearly showed 
that functional glycine receptors are not present on immune cells. This is in 
contrast to the published work by Wheeler et al (2000), which in conjunction with 
studies on Kupffer cells (liver macrophages) and alveolar macrophages (Ikejima et 
a l, 1997; Wheeler and Thurman, 1999; Froh et a l, 2002), suggested that glycine 
has anti-inflammatory effects and could be useful in many disease states which are 
dependent on the activation of leukocytes and macrophages (Wheeler et a l, 1999b, 
Froh et a l, 2002). However, our data do not support such suggestions.
The data obtained from the FACS studies in this project showed that application of 
GABA and muscimol leads to a small inhibition of fMLP and LPS induced [Ca^ j^, 
release from human and rat PBMCs. Based on the mRNA and protein expression 
studies, any functional GABAa receptors present on the immune cells would 
contain the a l subunit, and that the inhibition of [Ca^ J^j release could be taking 
place via the interaction of GABA and GABA agonists with these receptors. 
Various blood cells including lymphocytes have been shown to contain GABA 
and/or GABA related enzymes, and GABA-related metabolic enzymes have been 
involved in autoimmune diseases (Erdo and Wolff, 1990; Solimena et a l, 1990; 
Kaufman et a l, 1993; Tisch et a l, 1993; Schor et a l, 2001). Specific GABAa 
receptor binding sites have also been identified in platelet membranes (Oset-Gasque 
et a l, 1986; Bergeret et.al, 1998), and GABA levels in the thymus have been 
shown to increase during an immune response (Hall et a l, 1985). Studies have also 
shown that proliferation of thymic cells and splenic lymphocytes is modulated by 
GABAa receptors (Pawlikowski et a l, 1987, Pawlikowski et a l, 1988).
GABA and GAD have also been shown to have inhibitory effects in the 
development of insulin-dependent diabetes mellitus, as the insulin producing p-cells 
also secrete GABA which may reach sufficient levels to down-regulate infiltrating 
effector T cells (Rorsman et al., 1989). Also, Wan et al. (1997) showed that insulin
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can up-regulate neuronal GABAa receptor expression. Therefore, if insulin also 
increases GABAa receptors on islet-infiltrating T cells, it could enhance the 
immuno-inhibitory effect of GABA on T cell function. Bergeret et al. (1998) 
investigated a possible contribution of GABA to the physiology of immune 
competent cells, and reported that GABA modulates T cell-mediated cytotoxicity, 
probably via GABAa receptors, indicating that GABA can modulate immune cell 
functions. These findings agree with work published by Tian et al (1999) showing 
that GABAa receptors can mediate inhibition of mouse T cell responses. 
Therefore, the presence of functional GABAa receptors on immune cells could 
provide new approaches to modulate leukocyte responses in inflammatory diseases.
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